Conditions: Atopic Dermatitis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 12
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with Atopic Dermatitis

Detailed description:
This is an open-labeled exploratory study to evaluate safety and efficacy of FB825 in adults with atopic dermatitis (AD). The study will be conduct at one medical center in Taiwan.

Approximately 12 subjects with atopic dermatitis (AD), who meet the criteria for study entry, will be enrolled to the one-arm-study.

Arms:
arm 1: Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.

Interventions: intervention 1: FB825, FB825-15D11, Anti-CemX
Intervention descriptions: intervention 1: Pharmaceutical form: 20mg/ml solution Route of administration: IV

Protocol document:
Prot_SAP_000.pdf: 
 
1 
 
 
Clinical Study Protocol 
 
An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 
in Adults with Atopic Dermatitis 
PROTOCOL NO. FB825CLIIS-01-AD 
 
Study Protocol Number 
FB825CLIIS-01-AD 
Version and Date of Protocol: V1.3 Final, 02-March-2018 
• Investigational Product: 
FB825-15D11, FB825, h4B12  
(A humanized monoclonal antibody) 
• Indication 
Moderate-to-Severe Extrinsic Atopic Dermatitis 
• Drug Development 
Phase: 
Exploratory study 
• Principal Investigator:  
Dr. Chia-Yu Chu 
National Taiwan University Hospital  
 
• Sponsor: 
Fountain BioPharma Inc 
19F-1, No. 3, Yuan Qu St. 
Taipei 115, Taiwan 
Telephone: 886-2-2655-8687 
 
 
 
 
CONFIDENTIAL 
---------------------------------------------------------------------------------------------------------------------------- 
The concepts and information contained in this document or generated during the study are considered 
proprietary and may not be disclosed in whole or in part without the expressed, written consent of Fountain 
BioPharma Inc. 
 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
2 
Confidential 
Signature Page 
 
PROTOCOL TITLE: 
An Open-Labeled Exploratory Study to Evaluate Safety and 
Efficacy of FB825 in Adults with Atopic Dermatitis 
 
 
PROTOCOL NUMBER:
FB825CLIIS-01-AD 
 
Grace Huang 
President 
Fountain BioPharma Inc 
 
Date 
Nien-Yi Chen, PhD 
Vice President 
Fountain BioPharma Inc 
 
Date 
David Yeh 
Senior Director 
Department of Clinical Research 
Fountain BioPharma Inc 
 
Date 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
3 
Confidential 
Investigator Protocol Agreement Page 
 
PROTOCOL TITLE: 
An Open-Labeled Exploratory Study to Evaluate Safety and 
Efficacy of FB825 in Adults with Atopic Dermatitis 
PROTOCOL NUMBER:
FB825CLIIS-01-AD 
I agree to conduct the study as outlined in the protocol “FB825CLIIS-01-AD” in accordance with 
applicable standard operating procedures, ICH Good Clinical Practices, Good Laboratory 
Practices (GLP) and all other applicable regulations, including the recommendations laid down in 
the most recent version of the Declaration of Helsinki. I have read and understood all sections of 
the protocol. 
 
 
 
Dr. Chia-Yu Chu 
National Taiwan University Hospital 
 
 
 
 
Date 
 
 
 
 
 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
4 
Confidential 
Table of Contents 
Signature Page ................................................................................................................................ 2 
Investigator Protocol Agreement Page............................................................................................ 3 
Table of Contents ............................................................................................................................ 4 
List of Tables ................................................................................................................................... 7 
Protocol Synopsis............................................................................................................................ 8 
List of Abbreviations..................................................................................................................... 16 
1 
Introduction .......................................................................................................................... 18 
1.1 
Background ............................................................................................................18 
1.2 
FB825 .....................................................................................................................19 
1.3 
Non-clinical Data ...................................................................................................20 
1.3.1 
Nonclinical Pharmacology ........................................................................20 
1.3.2 
Toxicology Summary ................................................................................20 
1.3.3 
Single-Dose Studies ..................................................................................21 
1.3.4 
Repeat-Dose Studies .................................................................................22 
1.4 
Clinical Study.........................................................................................................24 
1.5 
Rationale for Study ................................................................................................25 
1.6 
Rationale for Dose Selection .................................................................................25 
2 
Study Objectives ................................................................................................................... 26 
2.1 
Primary Objective ..................................................................................................26 
2.2 
Secondary Objectives.............................................................................................26 
3 
Study Design ........................................................................................................................ 27 
4 
Selection of Study Population .............................................................................................. 28 
4.1 
Inclusion Criteria ...................................................................................................28 
4.2 
Exclusion Criteria ..................................................................................................29 
4.3 
Restrictions for Subject during the Study ..............................................................32 
4.4 
Withdrawal of Subjects from the Study .................................................................32 
4.4.1 
Reasons for Withdrawal ............................................................................32 
4.4.2 
Handling of Withdrawal ...........................................................................33 
5 
Study Treatments .................................................................................................................. 34 
5.1 
Identity of Study Treatments ..................................................................................34 
5.1.1 
Investigational Product (IP) (FB825) .......................................................34 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
5 
Confidential 
5.1.2 
Diluent ......................................................................................................34 
5.2 
Dosing and IV Administration of Study Treatments ..............................................34 
5.3 
Management of Clinical Supplies ..........................................................................35 
5.3.1 
Study Treatments Storage .........................................................................35 
5.3.2 
Study Drug Accountability .......................................................................35 
5.3.3 
Treatment Compliance ..............................................................................36 
5.4 
Prior, Concomitant and Prohibited Medications ....................................................36 
5.4.1 
Prior Medications and Therapies ..............................................................36 
5.4.2 
Pre-treatment/Concomitant Medication and Procedures ..........................36 
5.5 
Handling of Infusion-Related or Allergic Reaction ...............................................39 
5.5.1 
Rescue medications/procedures ................................................................39 
5.6 
Precautions .............................................................................................................40 
6 
Study Procedures and Methods of Assessment .................................................................... 41 
6.1 
Endpoints ...............................................................................................................41 
6.1.1 
Primary Endpoints ....................................................................................41 
6.1.2 
Secondary Endpoints ................................................................................41 
6.2 
Biomarker Assessments .........................................................................................42 
6.3 
Clinical Efficacy Assessments ...............................................................................43 
6.4 
Safety Assessments ................................................................................................44 
6.4.1 
Adverse Events .........................................................................................44 
6.4.2 
Physical Examinations ..............................................................................44 
6.4.3 
Vital Sign Measurements ..........................................................................45 
6.4.4 
Clinical Laboratory Testing ......................................................................45 
6.4.5 
Electrocardiograms ...................................................................................47 
6.5 
Other Assessments .................................................................................................47 
6.5.1 
Informed Consent and Subject Identification ...........................................47 
6.5.2 
Screening and Subject Number ................................................................48 
6.5.3 
Demographic Data ....................................................................................48 
6.5.4 
Medical History and Concomitant Medications .......................................48 
6.6 
Schedule of events .................................................................................................49 
7 
Adverse Events ..................................................................................................................... 52 
7.1 
Definitions..............................................................................................................52 
7.1.1 
Adverse Event (AE) ..................................................................................52 
7.1.2 
Serious Adverse Event (SAE) ...................................................................53 
7.1.3 
Adverse Events of Special Interest ...........................................................54 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
6 
Confidential 
7.2 
Eliciting of Adverse Events ...................................................................................54 
7.3 
Documenting Adverse Events ................................................................................55 
7.3.1 
Assessment of Severity .............................................................................55 
7.3.2 
Assessment of Causality ...........................................................................56 
7.3.3 
Follow-up of Adverse Events ...................................................................56 
7.4 
Reporting Serious Adverse Events .........................................................................57 
8 
Statistical Analysis ................................................................................................................ 58 
8.1 
General Statistics ...................................................................................................58 
8.2 
Sample Size Calculations .......................................................................................58 
8.3 
Analysis Sets ..........................................................................................................58 
8.4 
Statistical Analysis .................................................................................................59 
8.4.1 
Biomarker Analyses ..................................................................................59 
8.4.2 
Clinical Efficacy Analysis ........................................................................59 
8.4.3 
Safety Analyses .........................................................................................59 
8.5 
Handling of Missing Data ......................................................................................60 
8.6 
Interim Analyses ....................................................................................................60 
8.7 
Data Quality Assurance..........................................................................................60 
9 
Investigator Obligations ....................................................................................................... 61 
9.1 
Confidentiality .......................................................................................................61 
9.2 
Institutional Review ...............................................................................................61 
9.3 
Subject Consent .....................................................................................................62 
9.4 
Study Reporting Requirements ..............................................................................62 
9.5 
Financial Disclosure and Obligations ....................................................................62 
9.6 
Investigator Documentation ...................................................................................63 
9.7 
Study Conduct ........................................................................................................63 
9.8 
Data Collection ......................................................................................................64 
9.8.1 
Case Report Forms and Source Documents .............................................64 
9.9 
Adherence to Protocol............................................................................................64 
9.10 Reporting Adverse Events......................................................................................64 
9.11 Investigator’s Final Report ....................................................................................65 
9.12 Records Retention ..................................................................................................65 
9.13 Publications ............................................................................................................65 
10 
Study Management ............................................................................................................... 66 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
7 
Confidential 
10.1 Monitoring .............................................................................................................66 
10.1.1 Monitoring of the Study............................................................................66 
10.1.2 Inspection of Records ...............................................................................66 
10.2 Management of Protocol Amendments and Deviations.........................................66 
10.2.1 Modification of the Protocol .....................................................................66 
10.2.2 Protocol Violations and Deviations ..........................................................66 
10.3 Study Termination ..................................................................................................67 
10.4 Final Report ...........................................................................................................67 
11 
Reference List ....................................................................................................................... 69 
12 
Appendices ........................................................................................................................... 71 
12.1 Appendix 1: National Cancer Institute Common Terminology Criteria for Adverse 
Events v4.03 ...........................................................................................................71 
12.2 Appendix 2: Second symposium on the definition and management of anaphylaxis: 
Summary report—Second National Institute of Allergy and Infectious Disease/Food 
Allergy and Anaphylaxis Network symposium .....................................................72 
12.3 Appendix 3: Division of Microbiology and Infectious Disease (DMID) Adult Toxicity 
Table November 2007 Draft (For Screening) ........................................................73 
 
List of Tables 
Table 6.5-1 
Schedule of Events ................................................................................................ 49 
Table 12.2-1 Clinical Criteria for Diagnosing Anaphylaxis....................................................... 72 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
8 
Confidential 
Protocol Synopsis 
Sponsor: 
Fountain BioPharma Inc 
Protocol Number: 
FB825CLIIS-01-AD 
Developmental 
Phase: Exploratory 
study 
Title: 
An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults with 
Atopic Dermatitis 
Study Phase: 
Exploratory study 
PI and Study Site: 
Dr. Chia-Yu Chu;   
National Taiwan University Hospital  
Objectives:  
Primary Objective  
The primary objective of this study is: 
• To evaluate the change from baseline in total IgE and allergen-specific IgE in patients 
with atopic dermatitis after the IV administration of FB825. 
Secondary Objectives 
The secondary objectives of this study are: 
• To evaluate the clinical efficacy in patients with atopic dermatitis after the IV 
administration of FB825. 
• To explore the safety in patients with atopic dermatitis after the IV administration of 
FB825. 
• To monitor the changes in clinical hematology after the IV administration of FB825 
• To explore the change from baseline in biomarkers including thymus and activation 
regulated chemokine (TARC), Eotaxin-3, thymic stromal lymphopoietin (TSLP), 
periostin, IL-1a, IL-4, IL-5, IL-13, IL-16, IL-31 and M-CSF after IV administration of 
FB825. 
Study Design and Methodology: 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
9 
Confidential 
Sponsor: 
Fountain BioPharma Inc 
Protocol Number: 
FB825CLIIS-01-AD 
Developmental 
Phase: Exploratory 
study 
This is an open-labeled exploratory study to evaluate safety and efficacy of FB825 in adults 
with atopic dermatitis (AD). The study will be conduct at one medical center in Taiwan. 
Approximately 12 subjects with atopic dermatitis (AD), who meet the criteria for study entry, 
will be enrolled to the study. All eligible subjects will receive FB825, 5mg/kg, by 1-hour IV 
infusion on Day 1 and Day 85. Subjects will be hospitalized after receiving FB825 on Day 1 
and Day 85, and will be discharged from the hospital next day for safety observation (at least 
12 hours). Subjects will return to the study site on Days 8, 15, 29, 57, 92, 99, 113, 141, and 169 
for the safety, efficacy, and biomarker evaluation. Subjects who premature withdraw from the 
study will have an end of study (EOS) visit within 7 days. 
Serum total IgE and antigen-specific IgE will be measured at scheduled visits and evaluated to 
explore the changes from baseline after the IV administration of 5mg/kg FB825. Subjects will 
perform the activities at scheduled visits for clinical efficacy evaluation including Pruritus 
Visual Analogue Scale (VAS), Eczema Area and Severity Index (EASI), Severity Scoring of 
Atopic Dermatitis Index (SCORAD), Investigator Global Assessment (IGA) for AD and Body 
Surface Area (BSA) involved in AD symptoms.  
Safety data, including AEs and laboratory tests, will be reviewed by the PI. The duration of 
subject participation the study, excluding screening, is approximately 24 weeks.  
Study Drug, Dosage, and Route of Administration: 
Investigational Product (IP) 
FB825: A humanized monoclonal immunoglobulin G1 (IgG1) targeting the CεmX domain on 
human B lymphocytic cells expressing membrane-bound IgE (mIgE) 
FB825, 5mg/kg, is administered as single 1-hour IV- infusions. 
Inclusion criteria: 
1. Male or female subjects between 20 and 65 years of age, inclusive. 
2. The subject has a physician-confirmed diagnosis of chronic atopic dermatitis based on 
3 years history of symptoms defined by the Eichenfield revised criteria of Hannifin and 
Rajka and supported by positive allergen-specific IgE at the screening visit. 
3. Eczema Area and Severity Index (EASI) score ≧14 at the screening and baseline 
visits.  
4. Investigator’s Global Assessment (IGA) score ≧ 3 (5-point scale) at the screening and 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
10 
Confidential 
Sponsor: 
Fountain BioPharma Inc 
Protocol Number: 
FB825CLIIS-01-AD 
Developmental 
Phase: Exploratory 
study 
baseline visits. 
5. ≧10 % body surface area (BSA) of AD involvement at the screening and baseline 
visits. 
6. History of inadequate response to a stable (1 month) regimen of topical corticosteroids 
or calcineurin inhibitors as treatment for AD within 3 months before the screening 
visit. (The regimen of topical corticosteroids means medium to high potency, applied 
for at least 28 days or for the maximum duration recommended by product prescribing 
information.) 
7. Patients must be applying stable doses of emollient provide d for atopic dermatitis 
twice-daily for at least 7 days before the baseline visit.  
8. Female subjects of childbearing potential must use at least two forms of birth control. 
One must be barrier protection (i.e., condom or female condom) and the other is one of 
acceptable method of birth control (ie, diaphragm, intrauterine device, hormonal 
contraceptives, or abstinence) throughout the study. Subjects who are surgically sterile 
(ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or 
postmenopausal (defined as amenorrhea for 12 consecutive months and documented 
serum follicle-stimulating hormone level >40 mU/mL) will be considered as no 
childbearing potential. All female subjects must have a negative serum pregnancy test 
at prior to dosing. 
Note: The subject must use the method of contraception mentioned above during study 
period and in 16 weeks or 5 half-lives after the last dosing of FB825. 
9. The subject has a body weight ≥ 40 kg at screening and a body mass index of 18.0 to 
30.0 kg/m2, inclusive. 
10. The subject has a normal, as determined by the investigator, 12-lead electrocardiogram 
(ECG) with normal cardiac conduction parameters: 
 Heart rate between 45 and 100 bpm; 
 Fridericia-corrected QT interval (QTcF) ≤450 milliseconds (men) or ≤470 
milliseconds (women); 
 QRS interval lower than 120 milliseconds. 
11. The subject is healthy, except atopic diseases, as determined by the investigator, on the 
basis of clinical laboratory test results performed at screening. If the results are outside 
the normal reference ranges, the subject may be included only if the investigator judges 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
11 
Confidential 
Sponsor: 
Fountain BioPharma Inc 
Protocol Number: 
FB825CLIIS-01-AD 
Developmental 
Phase: Exploratory 
study 
the abnormalities or deviations from normal not to be clinically significant. This 
determination must be recorded in the subject’s source document and initialed by the 
investigator. This is not applicable to the laboratory abnormalities listed in the 
exclusion criterion (using the Division of Microbiology and Infectious Diseases 
criteria). 
12. The subject is able to provide written informed consent. 
13. The subject agrees to comply with all protocol requirements. 
Exclusion criteria: 
1. Female subjects who are pregnant or lactating. 
2. The subject is on diet or with poor intake. 
3. The subject has a history of heart arrhythmias (any clinically relevant). 
4. The subject has a positive test result for hepatitis B surface antigen, hepatitis C virus 
antibody, or human immunodeficiency virus antibodies at screening. 
5. The subject has a history of alcohol or drug abuse that would impair or risk the patients’ 
full participation in the study, in the opinion of the investigator. 
6. The subject is under judicial supervision or curatorship. 
7. The subject has a clinically relevant, currently active or underlying gastrointestinal, 
cardiovascular, nervous system, psychiatric, metabolic, renal, hepatic, respiratory 
(with the exception of uncomplicated allergic rhinitis), inflammatory, immunological, 
endocrine, diabetes, or infectious disease and ineligible to participate in the study 
judged by investigator. 
8.  The subject has any history of a previous anaphylactic reaction. 
9. The subject has any condition that, in the opinion of the investigator, would 
compromise the study or the well-being of the subject or prevent the subject from 
meeting or performing study requirements. 
10. The subject has received any immunoglobulin products or blood products within 3 
months prior to dosing. 
11. The subject has received a biologic product: 
 
The subject has received any cell-depleting agents, not only limited to rituximab, 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
12 
Confidential 
Sponsor: 
Fountain BioPharma Inc 
Protocol Number: 
FB825CLIIS-01-AD 
Developmental 
Phase: Exploratory 
study 
within 6 months prior to dosing, or before the lymphocyte count returns to normal, 
whichever is longer. 
 
The subject has received other biologics within 5 half-lives (if known) or 16 weeks, 
which is longer, prior to dosing). 
12. The subject has one or more of the following laboratory abnormalities at screening as 
defined by Division of Microbiology and Infectious Diseases Adult Toxicity Table, 
2007: 
 
Aspartate aminotransferase or alanine aminotransferase (>2 × upper limit of 
normal [ULN]) or higher 
 
Total bilirubin ≥1.5× ULN 
 
Serum creatinine ≥1.6 × ULN 
 
Any other laboratory abnormality higher than or equal to grade 2 with the 
exception of IgE level, eosinophil counts, eosinophil cationic protein (ECP) 
and laboratory values mentioned above. 
Note: Laboratory values may be converted to equivalent standard units. Retesting of 
abnormal laboratory values that may lead to exclusion will be allowed once (without 
prior sponsor approval). Retesting will take place during an unscheduled visit in the 
screening phase (before baseline). 
13. The subject has received any approved or unapproved (ie, investigational) 
immunotherapy treatment within the past 3 months. 
14. The subject has used any of the following classes of medication (prescription or over 
the counter): 
 
Intranasal corticosteroid (eg, fluticasone propionate) within 30 days prior to 
dosing. 
 
Systemic corticosteroids (eg, prednisone) within 30 days prior to dosing. 
 
Leukotriene modifiers (eg, montelukast) within 30 days prior to dosing. 
 
Immunosuppressants (eg, gold salts, methotrexate, azathioprine, cyclosporine) 
within the past 30 days prior to dosing. 
 
Immunomodulating drugs (eg, IFN-γ) within the past 30 days prior to dosing. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
13 
Confidential 
Sponsor: 
Fountain BioPharma Inc 
Protocol Number: 
FB825CLIIS-01-AD 
Developmental 
Phase: Exploratory 
study 
 
Anti-IgE (eg, omalizumab) within the past 1 year prior to dosing. 
 
Allergen immunotherapy within the past 1 year prior to dosing. 
 
Orally inhaled corticosteroids (eg, budesonide) within the past 30 days prior to 
dosing. 
15. The subject has received phototherapy within 4 weeks prior to dosing. 
16. The subject has received live vaccine within 12 weeks prior to dosing. 
17. The subject has known or suspected history of immunosuppression, including history 
of opportunistic infections (eg, TB) per investigator judgment. 
18. The subject has history of malignancy within 5 years before the screening period. 
19. High risk of parasite infection 
• Risk factors for parasitic disease (living in an endemic area, chronic gastrointestinal 
symptoms, travel within the last 6 months to regions where geohelminthic infections are 
endemic, and/or chronic immunosuppression) 
AND 
• Evidence of parasitic colonization or infection on stool evaluation for ova and 
parasites. 
Note: stool ova and parasite evaluation will only be conducted in patients with risk factors 
and an eosinophil count more than twice the upper limit of normal 
Primary Endpoints: 
 
Change from baseline in total IgE at Day85 and Day 169/EOS. 
 
Change from baseline in allergen-specific IgE at Day 85 and Day 169/EOS. 
Endpoints for Biomarker: 
 
Change from baseline in total IgE at Day 8, 15, 29, 57, 85, 92, 99, 113, 141, and 169. 
 
Change from baseline in allergen-specific IgE at Day 8, 15, 29, 57, 85, 92, 99, 113, 141, 
and 169. 
 
Change from baseline in biomarkers including thymus and activation regulated 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
14 
Confidential 
Sponsor: 
Fountain BioPharma Inc 
Protocol Number: 
FB825CLIIS-01-AD 
Developmental 
Phase: Exploratory 
study 
chemokine (TARC), Eotaxin-3, thymic stromal lymphopoietin (TSLP), periostin, IL-1a, 
IL-4, IL-5, IL-13, IL-16, IL-31 and M-CSF after IV administration of FB825 at Days 
8,15, 29, 57, 85, 92, 99, 113, 141, and 169. 
Efficacy Endpoints: 
 
Changes from baseline in Pruritus Visual Analogue Scale (VAS) at Days 8, 15, 29, 57, 
85, 92, 99, 113, 141, and 169. 
 
Changes from baseline in Eczema Area and Severity Index (EASI) at Days 8, 15, 29, 57, 
85, 92, 99, 113, 141, and 169. 
 
Changes from baseline in Severity Scoring of Atopic Dermatitis Index (SCORAD) at 
Days 8, 15, 29, 57, 85, 92, 99, 113, 141, and 169. 
 
Changes from baseline in Investigator Global Assessment (IGA) for atopic dermatitis at 
Days 8, 15, 29, 57, 85, 92, 99, 113, 141, and 169. 
 
Changes from baseline in Body Surface Area (BSA) involved in atopic dermatitis at Days 
8, 15, 29, 57, 85, 92, 99, 113, 141, and 169. 
Safety Assessments: 
Safety will be assessed by monitoring and recording of adverse events (AEs) and serious 
adverse event (SAEs); physical examination findings and vital sign measurements (systolic 
and diastolic blood pressures, heart rate, respiratory rate, and body temperature), clinical 
laboratory test results (hematology, coagulation, serum chemistry [including liver function 
tests, blood glucose level], and urinalysis); 12-lead ECG results. 
Sample Size: 
Approximately 12 evaluable subjects are planned for this study. The sample size for this study 
is based on clinical and practical considerations and not on a formal statistical power 
calculation.  
Statistical Methods: 
Concentration and change from baseline in total and allergen-specific IgE will be summarized 
by time point and presented graphically. Change from baseline in total and allergen-specific 
IgE will also be summarized by the baseline total IgE concentration (serum IgE>1500IU/mL 
or serum IgE ≤1500IU/mL) and given FB825 doses. The clinical endpoints will be analysed 
using descriptive statistic (mean of EASI, SCORAD, IGA, VAS, and BSA; SD, CV, number 
of subjects) by visit and given FB825 doses.  


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
15 
Confidential 
Sponsor: 
Fountain BioPharma Inc 
Protocol Number: 
FB825CLIIS-01-AD 
Developmental 
Phase: Exploratory 
study 
Adverse events will be coded by preferred term and system organ class (SOC) using the latest 
version of the Medical Dictionary for Regulatory Activities (MedDRA). Adverse events will 
also be summarized but not limited to severity, relationship to study drug, serious AEs, and 
AEs leading to discontinuation of study drug. 
Clinical laboratory test results including hematology, coagulation, serum chemistry, and 
urinalysis will be presented in data listings. Actual value and changes from baseline for clinical 
laboratory test results and vital sign measurements will be summarized by descriptive statistics 
(number of subjects, mean, SD, median, minimum, and maximum). Shift tables will be 
generated for clinical laboratory test results. Physical examination and 12-lead ECG findings 
will be presented in a data listing. 
 
Date of Protocol: 
02-March-2018 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
16 
Confidential 
List of Abbreviations 
Abbreviation 
Definition 
AD 
Atopic Dermatitis 
ADCC 
Antibody-Dependent Cellular Cytotoxicity 
AE 
Adverse Event 
ALT 
Alanine Aminotransferase 
AST 
Aspartate Aminotransferase 
AUC 
Area under the Concentration 
BCRs 
B-Cell Antigen Receptors 
BSA 
Body Surface Area 
Cmax 
Maximum Observed Concentration 
CNS 
Central Nervous System 
CRF 
Case Report Form 
CTCAE 
Common Terminology Criteria for Adverse Events 
EASI 
Eczema Area and Severity Index 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
ECP 
Eosinophil Cationic Protein 
ELISA 
Enzyme-Linked Immunosorbent Assay 
EOS 
End of Study 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GLP 
Good Laboratory Practice 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonisation 
Ig 
Immunoglobulin  
IGA 
Investigator Global Assessment 
IFN-γ 
Interferon-gamma 
IL 
Interleukin 
IP 
Investigational Product 
IRB 
Institutional Review Board 
IV 
Intravenous 
mAb 
Monoclonal Antibody 
MedDRA 
Medical Dictionary for Regulatory Activities 
mIgE 
Membrane-bound Immunoglobulin E 
M-CSF 
Macrophage colony stimulating factor 
NOAEL 
No Observed Adverse Effect Level 
NRS 
Numerical Rating Scale 
PBMCs 
Peripheral Blood Mononuclear Cells 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
17 
Confidential 
Abbreviation 
Definition 
PK 
Pharmacokinetic 
QTc 
Corrected QT interval 
QTcF 
Fridericia-corrected QT Interval 
SAE 
Serious Adverse Event 
SC 
Subcutaneous 
SCID 
Severe Combined Immunodeficiency  
SCORAD 
Severity Scoring of Atopic Dermatitis Index 
SD 
Standard Deviation 
SOC 
System Organ Class 
TARC 
Thymus and activation regulated chemokine 
TEAE 
Treatment-emergent adverse event 
TSLP 
Thymic stromal lymphopoietin 
t1/2 
terminal elimination half-life 
TCS 
Topical Corticosteroids 
ULN 
Upper Limit of Normal 
UV 
Ultraviolet 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
18 
Confidential 
1 Introduction 
1.1 Background 
Allergic diseases, such as atopic dermatitis, allergic asthma/ rhinitis, food allergies, and other type 
I hypersensitivity inflammatory disorders are among the fastest growing chronic diseases in the 
industrialized countries, and afflict 20%-40% of the population worldwide. Although some of 
these allergic disorders can be treated by medicines that directly easing the symptoms, many 
moderate- to-severe diseases remain poorly controlled, which not only exerts a huge impact on the 
life quality, but also high economic cost to the individual, family, and society. It is recognized that 
Immunoglobulin E (IgE) plays an important role in mediating hypersensitivity reactions 
responsible for most of the allergic diseases. IgE is produced by IgE-secreting plasma cells that are 
generated from continuous differentiation of B lymphocytes expressing membrane-bound IgE 
(mIgE) on the cell surface (Murphy 2011). The pharmaceutical development of anti-IgE 
omalizumab has validated the IgE pathway as an effective therapeutic target for treating 
IgE-mediated allergic diseases (Chang 2000). Omalizumab efficiently neutralizes free IgE, which 
down-regulates FcεRI on basophils, dendritic cells, and mast cells, thus successfully modulating 
allergic asthma. 
In “atopic” individuals who are at increased risk of developing allergies, IgE concentration in the 
circulatory system may reach over 10 times the normal level. The concentrations of 
allergen-specific IgE antibody are closely correlated with clinical symptoms and may be over 1000 
times higher in patients with allergic diseases than in those found in healthy individuals. IgE 
sensitizes effector cells such as basophils, mast cells, and activated eosinophils by occupying the 
high-affinity IgE receptor, FcεRI, on which they are expressed. In type I hypersensitivity, allergens 
cross-link IgE molecules bound by FcεRI and subsequently triggers the degranulation of effector 
cells, releasing pro-inflammatory mediators, such as histamines and leukotrienes. The 
IgE-mediated allergic pathway, which generates mediator-related allergic symptoms, initiates the 
immune activities locally or systemically. Basophils and mast cells also release a wide spectrum of 
inflammatory cytokines and chemokines that not only directly cause clinical symptoms but also 
activate and recruit various cell types to augment the inflammatory status. Hence, anti-IgE therapy 
can attenuate both the IgE-mediated pathway and the inflammatory conditions. The neutralization 
of IgE by humanized IgG antibodies has been studied in many clinical trials of allergic disorders 
(Vichyanond 2011); one of the anti-IgE IgG antibodies, omalizumab, (Xolair®; Genentech USA, 
Inc and Novartis Pharmaceuticals Corporation) has been approved for the treatment of allergic 
asthma and chronic idiopathic urticaria. The success of anti-IgE therapy has confirmed the role of 
IgE in the pathogenesis of asthma and gradually establishes the concept ‘‘allergic asthma’’. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
19 
Confidential 
IgE is biologically expressed in secretory form or membrane-bound form. Membrane-bound IgE 
forms the core unit of B-cell antigen receptors (BCRs) which determine antigen specificity and are 
essential for survival and functions of B cells. As a general rule in B-cell activation, besides 
crosslinking BCRs by specific antigens as the first signal, a second signal of co-stimulatory 
cytokines and receptor-ligand connection from cognate helper T cells is required. Without the 
appropriate co-stimulatory signal, a B cell who has its antigen receptors cross-linked will step on 
processes of energy, a state that is no longer responsive to antigens, or apoptosis. Therefore, an 
anti-CεmX targeting mIgE-expressing B cells, such as FB825, could be an effective agent to 
down-regulate activities of IgE-committed B lymphocytic cells. A drug product of mAb designed 
from similar rationale is being investigated by Roche Genentech which is referred to as quilizumab 
(h47H4; RG7449; MEMP1972A). Results of clinical studies showed that quilizumab can reduce 
IgE production in patients with allergic asthma (Gauvreau et al 2014). 
1.2 FB825 
Fountain Biopharma Inc developed FB825 to block the biological pathway of IgE synthesis; thus it 
could be used to treat IgE-mediated allergic diseases. FB825 is a humanized monoclonal 
immunoglobulin G1 specifically targeting the CεmX domain on human B lymphocytic cells 
expressing mIgE. The CεmX domain of 52 amino acid residues, located between the CH4 domain 
and membrane-anchor segment of human membrane-bound ε chain on mIgE+ B cells, is a unique 
antigenic site for the immunological targeting of B cells (Chen et al 2010; Peng et al 1992). 
Monoclonal antibodies specific for CεmX can potentially affect mIgE-expressing B lymphocytes 
and memory B cells, down-regulate IgE synthesis, and treat IgE-mediated allergic diseases (Chang 
2006; Chang et al 2007). FB825 binds specifically to the CεmX domain of mIgE and does not 
interact with free IgE; therefore, FB825 is not neutralized by IgE in the circulation.   
FB825 can bind to mIgE-expressing human B cells and induce subsequent apoptosis and/or 
antibody-dependent cellular cytotoxicity (ADCC) (Chan 2012; Cheng 2014). FB825 also reduces 
the number of IgE-producing plasma B cells in a culture of human peripheral blood mononuclear 
cells (PBMCs) (Li et al 2013). Furthermore, FB825 suppresses the anti-CD40- and 
interleukin-4-stimulated production of IgE from human PBMCs in a xenograft mouse model 
(Chou et al 2013). Based on the aforementioned findings, FB825 should be capable of blocking 
IgE production driven by allergens and alleviating airway hypersensitive symptoms like allergic 
asthma and rhinitis. Accumulating data exhibited that decreasing serum IgE levels probably helps 
alleviate atopic skin conditions like atopic dermatitis and chronic urticaria. If the pharmacological 
efficacy of FB825 can be proven in human clinical studies, its applications can be expanded to 
other IgE-mediated disorders. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
20 
Confidential 
By targeting CεmX domain, FB825 will not be consumed by free IgE. Therefore, unlike the 
situation met by omalizumab, its application may not be limited in patients with high serum IgE 
concentrations. According to Fountain Biopharma Inc pharmacological studies in pre-clinical 
stage, given the long theoretical half-life (t1/2) of human immunoglobulin G1 monoclonal 
antibodies, the systematic concentration of FB825 in a patient receiving a rational flat dose should 
be maintained above the minimal effective concentration to decrease the number of 
mIgE-expressing B cells and IgE production for several weeks. In comparison to omalizumab 
which is injected every 2 or 4 weeks, a seasonal treatment regimen of FB825 would be practicable, 
thus a long term control of hypersensitive symptoms would be expected. 
Additional details on FB825 are provided in the investigator’s brochure (IB) (Fountain BioPharma 
Inc 2017). 
1.3 Non-clinical Data 
Various in vitro, pharmacodynamic and GLP compliant toxicity studies have been conducted. 
Details of non-clinical studies are provided in the investigator’s brochure of FB825. 
1.3.1 Nonclinical Pharmacology 
Various in vitro and in vivo studies were performed to examine mechanisms of actions and 
pharmacological properties of FB825. Pharmacological properties are summarized as follows: 
• FB825 binds to mIgE+ B cells with high specificity.  
• FB825 shows similar affinity to the cynomolgus monkey and human CεmX domain. 
• FB825 induces cell death of mIgE+ B cells via ADCC and/or apoptosis in vitro and inhibits 
the growth of mIgE+ B-cells in mice. Complement-dependent cytotoxicity of FB825 was 
not detected.  
• FB825 shows pharmacological activities in the depletion of IgE-secreting B cells in 
primary culture of PBMCs obtained from atopic dermatitis patients. 
• FB825 inhibits IgE production of human PBMCs in severe combined immunodeficiency 
(SCID) mouse model. 
• Murine mAb 4B12 (parental clone of FB825) can specifically reduce antigen-specific IgE 
and reduce airway hyperresponsiveness to inhaled methacholine in an allergic asthma 
mouse model. 
1.3.2 Toxicology Summary 
The results of nonclinical toxicology studies of FB825 are summarized as follows: 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
21 
Confidential 
• FB825 was well-tolerated by cynomolgus monkeys at the maximum dose of 300 mg/kg in 
the single-dose toxicology studies via IV infusion or subcutaneous injection. 
• FB825 was well-tolerated in cynomolgus monkeys at levels of 30, 100, and 300 mg/kg via 
10-minute IV infusion once weekly for a total of 4 doses. FB825-related effects were 
limited to reversible marked increases in alanine aminotransferase (ALT) at FB825 doses 
of ≥100 mg/kg, and reversible mild increases in aspartate aminotransferase (AST), 
partially reversible minimal decreases in albumin levels and corresponding 
albumin:globulin ratios, and reversible minimal increases in monocyte counts at an FB825 
dose of 300 mg/kg. 
• FB825 was well-tolerated in cynomolgus monkeys at levels of 30, 100, and 200 mg/kg via 
20-minute IV infusion once every two weeks for 26 weeks. There are no adverse findings 
in clinical observations, body weights, body weight change, qualitative food consumption, 
ophthalmic observations, electrocardiograms, clinical and anatomic pathology, IgE, 
immunophenotyping (IPT) analysis, thyroid hormone (TSH and T4), and T cell-dependent 
antibody (anti-keyhole limpet hemocyanin [KLH] antibody) response. Therefore, the no 
observed adverse effect level (NOAEL) was 200 mg/kg/dose. 
• Tissue cross-reactivity of FB825 using cryosections from a full panel of human tissues 
showed minimal (1+) intensity positive cytoplasmic stainings, which were considered of 
uncertain specificity to Biotin-FB825, because cytoplasmic staining at very low intensity is 
occasionally noted as a nonspecific background finding. 
• Hyperimmunization study showed that the screening enzyme-linked immunosorbent assay 
(ELISA) detected FB825-reactive antibodies in the serum collected from all 3 animals 
tested. 
1.3.3 Single-Dose Studies 
Two non-GLP single-dose toxicity studies were carried out in cynomolgus monkeys. In an IV 
injection dose-range-finding study, a single 10-minute IV infusion of FB825 was well tolerated in 
male and female cynomolgus monkeys at levels of 30, 100, and 300 mg/kg. There were no 
treatment-related effects on clinical observations, food consumption, body weight, or mortality. 
FB825-related effects were limited to minimal increases in ALT and AST that recovered by Day 
57, and minimal increases to interleukin-6 and interleukin-10 at 6 hours and/or 1 hour after dosing 
in animals administered at least 100 mg/kg FB825. Based on these results, the no observed adverse 
effect level (NOAEL) was considered to be 300 mg/kg. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
22 
Confidential 
In another single-dose toxicology study, IV administration of FB825 via a single SC injection was 
well-tolerated in cynomolgus monkeys at 300 mg/kg. There were no FB825-related clinical signs 
or effects on body weights or clinical pathology parameters (hematology, coagulation, and clinical 
chemistry). 
1.3.4 Repeat-Dose Studies 
4-weeks study 
Two repeat-dose toxicity studies were carried out in cynomolgus monkeys. The first one IV 
administration of FB825 by 10 minute intravenous infusion once weekly for a total of 4 doses was 
well tolerated in cynomolgus monkeys at levels of 30, 100, and 300 mg/kg. The following 
parameters and end points were evaluated in this study: clinical signs, body weights, food 
consumption, ophthalmology, electrocardiology, clinical pathology parameters (hematology, 
coagulation, and clinical chemistry), bioanalysis and toxicokinetic evaluations, anti-therapeutic 
antibody analysis, flow cytometry, IgE analysis, thyroid hormone levels, gross necropsy findings, 
organ weights, and histopathologic examinations. 
There were no FB825-related clinical signs or effects on body weight, food consumption, 
ophthalmic, or electrocardiographic examinations, coagulation parameters, and thyroid hormone 
levels observed in either sex at doses up to 300 mg/kg. Additionally, there were no FB825-related 
notable gross findings at doses up to and including 300 mg/kg. 
FB825-related effects were limited to reversible marked increases in ALT at FB825 doses of ≥100 
mg/kg, and reversible mild increases in AST, partially reversible minimal decreases in albumin 
levels and corresponding albumin:globulin ratios, and reversible minimal increases in monocyte 
counts at an FB825 dose of 300 mg/kg. The magnitude of increases in ALT and AST levels at 300 
mg/kg were considered adverse. Target organ effects were observed at levels of ≥30 mg/kg and 
consisted of nonadverse follicular colloid depletion of the thyroid and lower thyroid weight. 
However, the lower thyroid weights were within the range observed in historical control monkeys. 
Because variation in colloid staining pattern, variation in thyroid follicle size, and vacuolar 
degeneration have been reported as spontaneous findings in cynomolgus monkeys (Ishida et al 
2000; Hatakeyama et al 2011) and because there were no test article-related effects on thyroxine 
and thyroid stimulating hormone levels, the findings in the thyroid were considered nonadverse 
under the conditions of this study. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
23 
Confidential 
Based on increases in ALT and AST levels at 300 mg/kg, the NOAEL was considered to be 100 
mg/kg (Cmax of 5,330,000 ng/mL and AUC(0-168h) of 520,000,000 ng•hr/mL for males and Cmax of 
5,220,000 ng/mL and AUC(0-168h) of 487,000,000 ng•hr/mL for females).. 
26 weeks study 
The second repeat dose study is IV administration of FB825 by 20 minute intravenous infusion 
once every other week for 26 weeks, which means for 13 doses, and assess the reversibility, 
persistence, or delayed occurrence of any effects after a 9-week recovery phase. FB825 was well 
tolerated in cynomolgus monkeys at levels of 30, 100, and 200 mg/kg.  
Assessment of toxicity was based on mortality, clinical observations, body weights, body weight 
change, qualitative food consumption, ophthalmic observations, electrocardiograms (ECGs), and 
clinical and anatomic pathology. Blood samples were collected for analyses of toxicokinetics, IgE, 
immunophenotyping (IPT), thyroid hormone (T4 and TSH), Immunogenicity (ADA) and T 
cell-dependent antibody (anti-keyhole limpet hemocyanin [KLH] antibody) response. 
All animals survived to the scheduled sacrifice. No FB825-related clinical observations or change 
in body weight, food consumption (qualitative), ECGs, ophthalmic examinations, hematology, 
coagulation, urinalysis, organ weights, macroscopic examination, thyroid hormone levels, IgE, 
IPT, anti-KLH antibody, or immunology were noted. 
Several non-progressive FB825-related clinical chemistry effects were observed at multiple time 
points during the dosing phase in animals administered ≥100 mg/kg/dose; these included a 
dose-related, minimally to moderately increased alanine aminotransferase activity, and a 
non-dose-related, minimally to mildly decreased albumin concentration (unclear mechanism), 
with accompanying minimally to mildly decreased albumin:globulin ratio in animals administered 
200 mg/kg/dose and minimally to mildly decreased calcium concentration in males administered 
≥100 mg/kg/dose. All changes were reversible, except that for calcium concentration, which was 
still decreased on Day 64 of recovery phase in males administered ≥100 mg/kg/dose. All changes, 
except for the increased alanine aminotransferase activity, were considered non-adverse based on 
their small magnitudes of change, absence of microscopic findings, and/or general evidence of 
reversibility. No FB825-related findings were observed in hematology, coagulation, or urinalysis 
test results. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
24 
Confidential 
At the terminal sacrifice, FB825-related microscopic findings were noted in the liver (minimal or 
slight individual hepatocyte necrosis, centrilobular hepatocyte vacuolation/degeneration/necrosis, 
diffuse leukocytosis in the sinusoidal lumen, and multifocal pigment of Kupffer cells), which were 
correlated with increased alanine aminotransferase (ALT) activity in most cases; and epidermis of 
the skin/subcutis (minimal or slight diffuse hyperplasia of the epidermis, accompanied by minimal 
hyperkeratosis) of animals administered ≥100 mg/kg/dose. These microscopic findings were 
reversible after a 9-week recovery phase, except the diffuse leukocytosis in the hepatic sinusoidal 
lumen of one male administered 100 mg/kg/dose; therefore, these microscopic findings were 
considered non-adverse. 
In conclusion, the 26 weeks repeat dose study resulted in no adverse findings in clinical 
observations. Therefore, the no observed adverse effect level (NOAEL) was 200 mg/kg/dose and 
this dose level corresponded to mean Cmax and AUC values are 7,590 µg/mL and 1,100,000 
µg*hr/mL, respectively, in male monkeys and 6,300 µg/mL and 882,000 µg*hr/mL, respectively, 
in female monkeys for FB825 on Day 169 of the dosing phase. 
Based on these two repeat-dose study, the no observed adverse effect level (NOAEL) of FB825 
was 200 mg/kg/dose. 
 
1.4 Clinical Study 
A phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, 
pharmacokinetics, and immunogenicity of single IV dose of FB825 in normal healthy subjects has 
been completed in the US, with US FDA approval. The study has included 54 subjects (by 2015) in 
6 dose cohorts of FB825: in doses of 0.003, 0.03, 0.3, 1.5, 5, and 10 mg/kg intravenously as a 
1-hour infusion. Study cohorts included 7 subjects each in Cohorts A and B (4 active: 3 placebo), 
and increased in subsequent cohorts to 10 subjects each in Cohorts C, D, E, and F (7 active: 3 
placebo).  
As of 30 Jan 2016, fifty-four subjects have received treatment with FB825/placebo in phase 1a 
study.  Currently, FB825 were well-tolerated up to 10 mg/kg IV in fifty four healthy volunteers in 
this phase 1a study.  


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
25 
Confidential 
1.5 Rationale for Study 
It is recognized that IgE plays an important role in mediating hypersensitivity reactions 
responsible for most of the allergic diseases, such as atopic dermatitis, asthma etc. which remain 
poorly controlled. FB825 blocks the biological pathway of IgE synthesis and thus can be used to 
treat IgE-mediated allergic diseases. 
FB825 was found to be safe when given IV repeat dose in toxicology study in monkey. No adverse 
effects of FB825 were observed in parameters included electrocardiograms for cardiovascular, 
ophthalmic examinations and other clinical, CNS and respiratory safety observations.  
The safety and tolerability of FB825 was demonstrated in the US phase I randomized, 
double-blind study with healthy subjects. Also, the FB825 was proved by in vivo study that it is 
able to block the biological pathway of IgE synthesis and thus can be used to treat IgE-mediated 
allergic diseases. Therefore, in this study, the effects of IgE in patients with atopic dermatitis 
receiving FB825 treatment will be investigated. The study will evaluate safety and efficacy in 
adults with atopic dermatitis. 
1.6 Rationale for Dose Selection 
A phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, 
pharmacokinetics, and immunogenicity of single IV doses of FB825 in normal healthy subjects 
has been completed in the US, with US FDA approval. The study has included 54 subjects (by 
2015) in 6 dose cohorts of FB825: in doses of 0.003, 0.03, 0.3, 1.5, 5, and 10 mg/kg intravenously 
as a 1-hour infusion. The results showed that FB825 was safe and well-tolerated up to 10 mg/kg IV 
in healthy volunteers. Based on the study results, 5 mg/Kg will be selected in the study because it is 
comparative safe and supposed to be effective. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
26 
Confidential 
2 Study Objectives 
2.1 Primary Objective 
The primary objective of this study is: 
• To evaluate the change from baseline in total IgE and allergen-specific IgE in patients with 
atopic dermatitis after the IV administration of FB825. 
2.2 Secondary Objectives 
The secondary objectives of this study are as follows: 
• To evaluate the clinical efficacy in patients with atopic dermatitis after the IV administration of 
FB825. 
• To explore the safety in patients with atopic dermatitis after the IV administration of FB825. 
• To monitor the changes in clinical hematology after the IV administration of FB825. 
• To explore the change from baseline in biomarkers including thymus and activation regulated 
chemokine (TARC), Eotaxin-3, thymic stromal lymphopoietin (TSLP), periostin, IL-1a, IL-4, 
IL-5, IL-13, IL-16, IL-31 and M-CSF after IV administration of FB825. 
 
 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
27 
Confidential 
3 Study Design 
This is an open-labeled exploratory study to evaluate safety and efficacy of FB825 in adults with 
atopic dermatitis. The study will be conducted at one center in Taiwan. 
Approximately 12 subjects with atopic dermatitis (AD), who meet the criteria for study entry, will 
be enrolled to the study. All eligible subjects will receive FB825, 5mg/kg, by 1-hour IV infusion 
on Day 1 and Day 85. Subjects will be hospitalized after receiving FB825 on Day 1 and Day 85 
and will be discharged from the hospital next day for safety observation (at least 12 hours). 
Subjects will return to the study site on Days 8, 15, 29, 57, 92, 99, 113, 141, and 169 for the safety, 
efficacy, and biomarker evaluation.  
 
 
 
 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
28 
Confidential 
4 Selection of Study Population 
Male or female subjects with atopic dermatitis will enrolled in a single study site. Approximately 
15 subjects in total will enrolled to achieve at least 12 evaluable subjects. 
4.1 Inclusion Criteria 
Each subject must meet all of the following criteria to be enrolled in this study: 
1. Male or female between 20 and 65 years of age, inclusive. 
2. The subject has a physician-confirmed diagnosis of chronic atopic dermatitis based on 3-year 
history of symptoms defined by the Eichenfield revised criteria of Hannifin and Rajka and 
supported by positive allergen-specific IgE at the screening visit. 
3. Eczema Area and Severity Index (EASI) score ≧14 at the screening and baseline visits.  
4. Investigator’s Global Assessment (IGA) score ≧ 3 (5-point scale) at the screening and 
baseline visits. 
5. ≧10 % body surface area (BSA) of AD involvement at the screening and baseline visits. 
6. History of inadequate response to a stable (1 month) regimen of topical corticosteroids or 
calcineurin inhibitors as treatment for AD within 3 months before the screening visit. (The 
regimen of topical corticosteroids means medium to high potency, applied for at least 28 days 
or for the maximum duration recommended by product prescribing information.) 
7. Patients must be applying stable doses of emollient provided for atopic dermatitis twice-daily 
for at least 7 days before the baseline visit.  
8. Female subjects of childbearing potential must use at least two forms of birth control. One 
must be barrier protection (i.e., condom or female condom) and the other is one of acceptable 
method of birth control (ie, diaphragm, intrauterine device, hormonal contraceptives, or 
abstinence) throughout the study. Subjects who are surgically sterile (ie, hysterectomy, 
bilateral tubal ligation, or bilateral oophorectomy), or postmenopausal (defined as amenorrhea 
for 12 consecutive months and documented serum follicle-stimulating hormone level >40 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
29 
Confidential 
mU/mL) will be considered as no childbearing potential. All female subjects must have a 
negative serum pregnancy test prior to dosing. 
Note: The subject must use the method of contraception mentioned above during study period 
and in 16 weeks or 5 half-lives after the last dosing of FB825. 
9. The subject has a body weight ≥ 40 kg at screening and a body mass index of 18.0 to 
30.0 kg/m2, inclusive. 
10. The subject has a normal, as determined by the investigator, 12-lead electrocardiogram (ECG) 
with normal cardiac conduction parameters: 
 
Heart rate between 45 and 100 bpm; 
 
Fridericia-corrected QT interval (QTcF) ≤450 milliseconds (men) or 
≤470 milliseconds (women); 
 
QRS interval lower than 120 milliseconds. 
11. The subject is healthy, except atopic diseases, as determined by the investigator, on the basis of 
clinical laboratory test results performed at screening. If the results are outside the normal 
reference ranges, the subject may be included only if the investigator judges the abnormalities 
or deviations from normal not to be clinically significant.  
12. The subject is able to provide written informed consent. 
13. The subject agrees to comply with all protocol requirements. 
4.2 Exclusion Criteria 
1. Female subjects who are pregnant or lactating. 
2. The subject is on diet or with poor intake. 
3. The subject has a history of heart arrhythmias (any clinically relevant). 
4. The subject has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
30 
Confidential 
or human immunodeficiency virus antibodies at screening. 
5. The subject has a history of alcohol or drug abuse that would impair or risk the patients’ full 
participation in the study, in the opinion of the investigator. 
6. The subject is under judicial supervision or curatorship. 
7. The subject has a clinically relevant, currently active or underlying gastrointestinal, 
cardiovascular, nervous system, psychiatric, metabolic, renal, hepatic, respiratory (with the 
exception of uncomplicated allergic rhinitis), inflammatory, immunological, endocrine, 
diabetes, or infectious disease and ineligible to participate in the study judged by investigator. 
8. The subject has any history of a previous anaphylactic reaction. 
9. The subject has any condition that, in the opinion of the investigator, would compromise the 
study or the well-being of the subject or prevent the subject from meeting or performing study 
requirements. 
10. The subject has received any immunoglobulin products or blood products within 3 months 
prior to dosing. 
11. The subject has received an biologic product: 
 
The subject has received any cell-depleting agents, not only limited to rituximab, within 6 
months prior to dosing, or before the lymphocyte count returns to normal, whichever is 
longer. 
 
The subject has received other biologics within 5 half-lives (if known) or 16 weeks, 
which is longer, prior to dosing). 
12. The subject has one or more of the following laboratory abnormalities at screening as defined 
by Division of Microbiology and Infectious Diseases Adult Toxicity Table 2007: 
 
Aspartate aminotransferase or alanine aminotransferase (>2 × upper limit of normal 
[ULN]) or higher 
 
Total bilirubin ≥1.5 × ULN 
 
Serum creatinine ≥1.6 × ULN 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
31 
Confidential 
 
Any other laboratory abnormality higher than or equal to grade 2 with the exception of 
IgE level, eosinophil counts, eosinophil cationic protein (ECP) and laboratory values 
mentioned above. 
Note: Laboratory values may be converted to equivalent standard units. Retesting of 
abnormal laboratory values that may lead to exclusion will be allowed once (without prior 
sponsor approval). Retesting will take place during an unscheduled visit in the screening 
phase (before baseline). 
13. The subject has received any approved or unapproved (ie, investigational) immunotherapy 
treatment within the past 3 months. 
14. The subject has used any of the following classes of medication (prescription or over the 
counter): 
 
Intranasal corticosteroid (eg, fluticasone propionate) within 30 days prior to dosing. 
 
Systemic corticosteroids (eg, prednisone) within 30 days prior to dosing. 
 
Leukotriene modifiers (eg, montelukast) within 30 days prior to dosing. 
 
Immunosuppressants (eg, gold salts, methotrexate, azathioprine, cyclosporine) within the 
past 30 days prior to dosing. 
 
Immunomodulating drugs (eg, IFN-γ) within the past 30 days prior to dosing. 
 
Anti-IgE (eg, omalizumab) within the past 1 years prior to dosing 
 
Allergen immunotherapy within the past 1 years prior to dosing 
 
Orally inhaled corticosteroids (eg, budesonide) within the past 30 days prior to dosing 
15. The subject has received phototherapy within 4 weeks prior to dosing. 
16. The subject has received live vaccine within 12 weeks prior to dosing. 
17. The subject has known or suspected history of immunosuppression, including history of 
opportunistic infections (eg, TB) per investigator judgment. 
18. The subject has history of malignancy within 5 years before the screening period. 
19. High risk of parasite infection. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
32 
Confidential 
• Risk factors for parasitic disease (living in an endemic area, chronic gastrointestinal 
symptoms, travel within the last 6 months to regions where geohelminthic infections are 
endemic, and/or chronic immunosuppression) 
AND 
•  Evidence of parasitic colonization or infection on stool evaluation for ova and parasites. 
Note: stool ova and parasite evaluation will only be conducted in patients with risk factors 
and an eosinophil count more than twice the upper limit of normal 
4.3 Restrictions for Subject during the Study 
• Subjects must be willing to remain in the hospital overnight after FB825 IV administration for   
safety observation (at least 12 hours) on Day 1 and Day 85. 
• Subjects must be willing to return to the clinic for every follow-up visit up to Day169 
(end-of-study visit). 
• Subjects must refrain from strenuous physical activity or contact sports 24 hours prior to 
dosing and during the safety observation period. 
• Subjects must refrain from alcohol consumption 48 hours prior to dosing and during the safety 
observation period. 
• Subjects may not travel to where endemic parasitic diseases occur. Site staff should discuss 
with the sponsor for guidance in cases of uncertainty. 
4.4 Withdrawal of Subjects from the Study 
4.4.1 Reasons for Withdrawal 
Subjects can withdraw consent and discontinue from the study at any time, for any reason, without 
prejudice to further treatment. 
The investigator may withdraw a subject from the study if the subject: 
1. Is in violation of the protocol 
2. Experiences a serious adverse event (SAE) or intolerable AE 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
33 
Confidential 
3. Has laboratory safety assessments that reveal clinically significant hematological or 
biochemical changes from baseline values 
4. Develops, during the course of the study, symptoms or conditions listed in the exclusion 
criteria 
5. Requires a medication prohibited by the protocol 
6. Requests an early discontinuation for any reason. 
The investigator can also withdraw a subject upon the request of Fountain or if Fountain terminates 
the study. Upon occurrence of an SAE or intolerable AE, the investigator will confer with the 
sponsor. If a subject is discontinued because of an AE, the event will be followed until it is 
resolved or until stable. 
4.4.2 Handling of Withdrawal 
When a subject withdraws from the study, the reason(s) for withdrawal will be recorded by the 
investigator in the relevant page of the case report form (CRF). Whenever possible, any subject 
who withdraws from the study prematurely will undergo all end-of-study assessments. Any 
subject who fails to return for final assessments will be contacted by the site in an attempt to have 
him or her comply with the protocol. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
34 
Confidential 
5 Study Treatments 
5.1 Identity of Study Treatments 
The Investigational Product (IP) FB825 drug product is manufactured by Cytovance Biologics, 
800 Research Parkway, Ste 200 | Oklahoma City, OK 73104 
5.1.1 Investigational Product (IP) (FB825) 
The FB825 drug substance is a recombinant humanized immunoglobulin gamma-1 mAb directed 
against the CεmX segment of human mIgE on the progenitors of IgE-secreting B cells. The mature 
FB825 molecule is a heterotetrameric polypeptide that consists of two 219 residue kappa light 
chains and two 447-residue heavy chains, with a molecular weight of 147.79 kDa. 
FB825 drug product as a sterile solution for injection, supplied as a 3.0-mL solution at a 
concentration of 20 mg/mL in a solution containing 20 mM L-histidine, 140 mM sodium chloride, 
and 0.02% Tween 80 at pH 6.5 with water for injection, without any preservative. The visual 
appearance of the solution of FB825 is clear, colorless, and with no visible particles. The product is 
packed in serum/lyophilization flint glass vial (5 mL vial, with a total amount of FB825 at 60 
mg/vial). The vial is fitted with a 20-mm serum-style stoppers and 20-mm Flip-off TruEdge red 
matted aluminum seal, intended for intravenous (IV) injection for single use.  
5.1.2 Diluent  
FB825 (3.0-mL solution in 5 mL glass vial) is to be diluted before use. The diluent, 0.9% sodium 
chloride solution for injection, will be supplied as a 250-mL volume pack. 
5.2 Dosing and IV Administration of Study Treatments  
Two doses of 5 mg/kg FB825 will be given to subjects with atopic dermatitis.   
Subjects will receive FB825 by 1-hour IV infusion in the morning at Day 1 and Day 85. Fasting for 
at least 2 hours will be required. There will be no restriction of when subjects can eat again after 
finishing the infusion. Water intake is not allowed within 1 hour prior to dosing and 1 hour after 
dosing (water can be had at other times). 
The administered amount of FB825 will be adjusted based on subject’s body weight, the 
appropriate amount of drug product will be diluted with 250 mL 0.9% sodium chloride solution. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
35 
Confidential 
FB825 will be administered via IV route over 1 hour with the aid of a programmable volumetric 
infusion device. 
The final diluted product with 0.9% sodium chloride, after reconstitution, has to be used as soon as 
possible, and has to be used with 8 hours. The reconstituted FB825 can be stored at 2°C to 25°C for 
a maximum of 8 hours, prior to use. 
5.3 Management of Clinical Supplies 
5.3.1 Study Treatments Storage 
Fountain will provide the investigator and study site with adequate quantities of IP FB825 drug. 
All study drugs must be stored in a secure area (eg, a locked cabinet), protected from moisture and 
light, and be stored at 2°C to 8°C. The site will be required to keep a temperature log to establish a 
record of compliance with these storage conditions. All study drugs will be kept in a secure cabinet 
or room with access restricted to necessary study site personnel. 
FB825 drug product vials will be shipped at 2°C to 8°C to the study site. Upon arrival, the vials of 
FB825 should be transferred to 2°C to 8°C, and may be stored for at least 9 months.  
For optimal performance, FB825 drug product should be diluted on the day of injection and used 
immediately. After the final dilution with 0.9% sodium chloride solution for injection, the FB825 
solution can be stored at 2°C to 25°C for a maximum of 8 hours. 
5.3.2 Study Drug Accountability 
The sponsor “Fountain” is responsible for shipping FB825 to the study site and strict inventory 
control for the drug accountability of the shipment received at the site should be implemented at 
the site.  
The investigator will maintain accurate records of receipt of all study drugs, including dates of 
receipt. In addition, accurate records will be kept regarding when and how much study drug is 
dispensed and used by each subject in the study. Reasons for departure from the expected 
dispensing regimen must also be recorded. At the completion of the study, to satisfy regulatory 
requirements regarding drug accountability, the study drug will be reconciled and retained or 
destroyed according to applicable regulations.  


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
36 
Confidential 
The clinic study site pharmacy will prepare a single dose for each subject. Separate instructions 
will be provided to the clinic for dose dilution, preparation, storage, and IV administration. 
5.3.3 Treatment Compliance 
Study drug will be administered in the clinic under direct observation of clinic personnel and 
recorded in the CRF. Clinic personnel will confirm that the subject has received the dose of study 
drug. 
The date and time of study drug dosing will be recorded in the appropriate page of the CRF. If a 
subject does not receive study drug, the reason for not receiving study drug will be recorded. 
5.4 Prior, Concomitant and Prohibited Medications 
5.4.1 Prior Medications and Therapies 
Information about prior medications taken by the subject within the 30 days before he or she 
provides informed consent will be recorded in the subject’s CRF. 
5.4.2 Pre-treatment/Concomitant Medication and Procedures 
Any treatment (including nutritional supplements) or procedure administered from the time of 
signing of the ICF to the end of study visit is considered concomitant and will be recorded in the 
CRF. This includes permitted medications ongoing at the time of consent.  
The AD basal therapy during the study described below: 
 
All patients are required to apply moisturizers at least twice daily for at least the 7 
consecutive days prior to dosing and to continue the treatment throughout the study. All 
types of moisturizers are permitted, but patients may not initiate treatment with 
prescription moisturizers or moisturizers containing additives during the screening period 
or during the study.   
 
Patients may continue using stable doses of prescription moisturizers or moisturizers 
containing additives, if initiated before the screening visit. Starting on day 1/baseline, all 
patients are required to initiate treatment with topical corticosteroid (TCS) using a 
standardized regimen according to the following guidelines:  


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
37 
Confidential 
 
Apply medium potency TCS daily to areas with active lesions  
 
Low potency TCS should be used on areas of thin skin (face, neck, 
intertriginous, and genital areas, areas of skin atrophy, etc.) or for areas where 
continued treatment with medium potency TCS is considered unsafe 
 
After lesions are under control (clear or almost clear), switch from medium potency 
to low potency TCS and treat daily for 7 days, then stop  
 
If lesions return, reinstitute treatment with medium potency TCS, with the 
step-down approach described above upon lesion resolution  
 
For lesions persisting or worsening under daily treatment with medium potency 
TCS, patients may be treated (rescued) with high or super-high potency TCS, unless 
higher potency TCS are considered unsafe  
 
Monitor the patient for signs of local or systemic TCS toxicity and step down or stop 
treatment as necessary  
 
The type and amount of topical products used during the study will be recorded. The 
amount of TCS used will be determined by weighing the tube at each visit (see study 
reference manual for details).  
 
It is recommended that patients use fluticasone propionate 0.05% cream, mometasone 
furoate 0.1% cream, or betamethasone valerate 0.06% cream as medium potency TCS, 
and hydrocortisone 1% ointment for low potency TCS.   
 
If rescue with TCS is needed, it is recommended that patients use fluocinonide 0.05 % 
cream, desoximetasone 0.25% ointment as high potency TCS, and clobetasol propionate 
0.05% ointment for super high potency TCS.   
 
Do not use moisturizers and TCS on the same areas at the same time during the day.  On 
areas not treated with TCS, moisturizers will be applied twice daily – morning and 
evening.  


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
38 
Confidential 
Pre-treatment medications/procedures: medications taken or procedures performed prior to 
dosing. 
Concomitant medications/procedures: medications taken or procedures performed following the 
IV administration of study drug through the EOS visit. 
Prohibited concomitant medications: 
• Topical tacrolimus and pimecrolimus 
• Systemic corticosteroids, unless the subjects are under rescue medication. 
• Leukotriene inhibitors 
• Allergen immunotherapy 
• Systemic treatment for AD with an immunosuppressive/immunomodulating substance 
(including, but not limited to, cyclosporine, mycophenolate-mofetil, IFN-γ, azathioprine, 
methotrexate, or biologics) 
• Treatment with a live (attenuated) vaccine 
• Traditional Chinese Medicine 
Prohibited concomitant procedures: 
• Surgical procedures 
• Concomitant ultraviolet (UV) procedures (phototherapy [NBUVB, UVB, UVA1, or 
PUVA]) 
• Tanning in a bed/booth is not allowed during the study 
• Patients are not allowed more than 2 bleach baths per week during study participation 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
39 
Confidential 
5.5 Handling of Infusion-Related or Allergic Reaction 
The IV administration of study drug must be performed under supervision of trained medical staff 
and where facilities to handle allergic reactions are available. If a subject experiences an 
infusion-related reaction, the subject must be treated symptomatically with supportive care, further 
monitoring, and appropriate medical therapy which may include antihistamines and/or 
corticosteroid if needed. The study infusion may be stopped and the subject will be followed until 
the end of the study. The amount infused will be recorded. Should a subject experience symptoms 
typical of an allergic reaction (eg, shortness of breath, anaphylaxis, urticaria, angioedema), then 
study drug IV administration should be discontinued immediately and permanently. 
Suspected anaphylaxis should be assessed according to the clinical diagnostic criteria outlined by 
the National Institute of Allergy and Infectious Diseases which are provided in Appendix 12-2. 
For these and other circumstances, subjects will receive appropriate medical treatment at the 
discretion of the investigator. 
5.5.1 Rescue medications/procedures 
At the discretion of the investigator, patients may be rescued with a prohibited medication or 
procedure to treat intolerable AD symptoms. 
 
If medically necessary (ie, to control intolerable AD symptoms), rescue treatment with 
systemic corticosteroids for AD at doses less than 1 mg/kg/day prednisolone and no more 
than 3 days may be provided to study patients at the discretion of the investigator after week 
2.  
 
Investigators should make every attempt to conduct efficacy and safety assessments (eg, 
disease severity scores, safety labs) immediately before administering any rescue treatment. 
An unscheduled visit may be used for this purpose if necessary.  
The IV administration of study drug must be performed under supervision of trained medical staff 
and where facilities to handle allergic reactions are available. The clinic should have a staff trained 
to manage anaphylaxis and cardiopulmonary arrest. At a minimum, the clinic will have a crash cart 
with appropriate monitoring and resuscitation equipment including IV replacement fluids, to be 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
40 
Confidential 
able to deliver supplementary oxygen, and provide appropriate medications including 
antihistamines, corticosteroids, and epinephrine. 
5.6 Precautions 
Based on the approved and marketed Xolair anti-IgE antibody product (Genentech 2014), the most 
common AEs (≥1% more frequent in Xolair-treated patients) in clinical studies for allergic asthma 
treatment were arthralgia, pain (general), leg pain, fatigue, dizziness, fracture, arm pain, pruritus, 
dermatitis, and earache. The most common AEs (≥2% Xolair-treated patients and more frequent 
than in placebo) in clinical studies for chronic idiopathic urticaria treatment were nausea, 
nasopharyngitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection, 
arthralgia, headache, cough, and injection site reactions. The use of Xolair has also been associated 
with anaphylaxis (boxed warning); malignancy; acute asthma symptoms; corticosteroid reduction; 
fever, arthralgia, and rash; and eosinophilic conditions. In controlled trials, a numerical imbalance 
in the number of arterial thrombotic events was noted between omalizumab and placebo. Cases of 
idiopathic thrombocytopenia have been noted through spontaneous reporting but the frequency of 
any potential association is not known. In Genentech’s Phase 1a single dose study with 
MEMP1972A, the most common AEs were headache, fatigue, vessel puncture site hematoma, and 
nasopharyngitis, and in their Phase IIa multiple-ascending dose study with MEMP1972A, the 
most common AEs were headache, nasal congestion, back pain, dizziness, and fatigue. Similar 
reactions may also occur in this study with FB825. 
 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
41 
Confidential 
6 Study Procedures and Methods of Assessment  
The following sections describe the study procedures and data to be collected. Subjects are to be 
assessed by the same investigator or site personnel whenever possible. 
6.1 Endpoints 
6.1.1 Primary Endpoints 
• Change from baseline in total IgE at Day85 and Day 169/EOS. 
• Change from baseline in allergen-specific IgE at Day 85 and Day 169/EOS. 
6.1.2 Secondary Endpoints 
 
Change from baseline in total IgE at Day 8, 15, 29, 57, 85, 92, 99, 113, 141, and 169. 
 
Change from baseline in allergen-specific IgE at Day 8, 15, 29, 57, 85, 92, 99, 113, 141, and 
169. 
 
Changes from baseline in pruritus Visual Analogue Scale (VAS) at Days 8, 15, 29, 57, 85, 92, 
99, 113, 141, and 169 
 
Changes from baseline in Eczema Area and Severity Index (EASI) at Days 8, 15, 29, 57, 85, 
92, 99, 113, 141, and 169 
 
Changes from baseline in Severity Scoring of Atopic Dermatitis Index (SCORAD) at Days 8, 
15, 29, 57, 85, 92, 99, 113, 141, and 169 
 
Changes from baseline in Investigator Global Assessment (IGA) for atopic dermatitis at Days 
8, 15, 29, 57, 85, 92, 99, 113, 141, and 169 
 
Changes from baseline in Body Surface Area (BSA) involved in atopic dermatitis at Days 8, 
15, 29, 57, 85, 92, 99, 113, 141, and 169 
 
Change from baseline in biomarkers including thymus and activation regulated chemokine 
(TARC), Eotaxin-3, thymic stromal lymphopoietin (TSLP), periostin, IL-1a, IL-4, IL-5, 
IL-13, IL-16, IL-31 and M-CSF after IV administration of FB825 at Days 8, 15, 29, 57, 85, 92, 
99, 113, 141, and 169 
 
Safety will be assessed by monitoring and recording of adverse events (AEs) and serious 
adverse event (SAEs); physical examination findings and vital sign measurements (systolic 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
42 
Confidential 
and diastolic blood pressures, heart rate, respiratory rate, and body temperature), clinical 
laboratory test results (hematology, coagulation, serum chemistry [including liver function 
tests, blood glucose level], and urinalysis); 12-lead ECG results. 
6.2 Biomarker Assessments 
Blood samples for the measurement of total, allergen-specific IgE, thymus and activation 
regulated chemokine (TARC), Eotaxin-3, thymic stromal lymphopoietin (TSLP), periostin, IL-1a, 
IL-4, IL-5, IL-13, IL-16, IL-31 and M-CSF will be analyzed according to methodology described 
in a separate report. 
Blood samples will be collected. The actual sample collection time and sampling problems, if any, 
will be recorded on the CRF. Approximately 5 mL sample of venous blood per sample will be 
drawn at the following time points: 
Total Immunoglobulin/ Allergen-specific IgE : 
 
Screening period: at any time  
 
Day 1, and 85: (In 2 hours  before the start of infusion) 
 
Days 8, 15, 29, 57, 92, 99, 113, and 141, and 169 after IV administration of FB825  at any 
time on the day. 
 
TARC, Eotaxin-3, TSLP, periostin, IL-1a, IL-4, IL-5, IL-13, IL-16, IL-31 and M-CSF: 
 
Day 1 and 85 in 2 hours before the start of infusion, and at any time on Days 8, 15, 29, 57, 92, 
99, 113, 141, and 169.. 
 
Instructions for sample collection, preparation, and shipping will be provided separately to the 
clinical site. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
43 
Confidential 
6.3 Clinical Efficacy Assessments 
Pruritus Visual Analogue Scale (VAS) 
The pruritus visual analogue scale (VAS) of SCORAD will be applied for the measurement of 
pruritus. Patients will be asked to assign a numerical score representing the intensity of their 
symptoms on a scale from 0 to 10, with 0 for having no symptoms and 10 having worst symptoms. 
Subjects will be asked to perform the measurement at screening, Day 1 and 85 before dosing, Day 
2 and Day 86 before discharge, and any time of Day 8, 15, 29, 57, 92, 99, 113, 141, and 169 
Severity Scoring of Atopic Dermatitis Index  (SCORAD) 
The SCORAD (Index) is the validated scoring system in atopic dermatitis (AD). To measure 
the extent of AD, the rule of nines is applied on a front/back drawing of the patient’s 
inflammatory lesions. The extent can be graded from 0 to 100. The intensity part of the 
SCORAD consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, 
oozing/crusts and dryness. Each item can be graded on a scale from 0 (absent) to 3 (severe). 
The subjective items include daily pruritus and sleeplessness. The SCORAD Index formula is: 
A/5 + 7B/2 + C. In this formula A is defined as the extent (0–100), B is defined as the intensity 
(0–18) and C is defined as the subjective symptoms (0–20). The maximal score of the 
SCORAD Index is 103. Subjects will be asked to perform the measurement at screening, Day 1, 
and 85 before dosing, Day 2 and Day 86 before discharge, and any time of Day 8, 15, 29, 57, 92, 99, 
113, 141, and 169. 
Eczema Area and Severity Index (EASI) 
The EASI scoring system uses a defined process to grade the severity of the signs of eczema and 
the extent affected. Extent and severity of signs of eczema will be evaluated in four body regions 
and the total score will be the sum of the four regions scores adjusted with multipliers. The EASI 
score is ranged from 0-72. Subjects will be asked to perform the measurement at screening, Day 1 
and 85 before dosing, Day 2 and Day 86 before discharge, and any time of Day 8, 15, 29, 57, 92, 99, 
113, 141, and 169. 
IGA for AD 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
44 
Confidential 
IGA allows investigators to assess overall disease severity at one given time point, and it consists 
of a 5-point severity scale from clear to very severe disease (0= clear, 1 =almost clear, 2 = mild 
disease, 3 = moderate disease, and 4= severe disease). Subjects will be asked to perform the 
measurement at screening, Day 1 and 85 before dosing, Day 2 and Day 86 before discharge, and 
any time of Day 8, 15, 29, 57, 92, 99, 113, 141, and 169. 
BSA involved in AD symptoms 
It will be measured as part A (Extent) of SCORAD. Subjects will be asked to perform the 
measurement at screening, Day 1 and 85 before dosing, Day 2 and Day 86 before discharge, and 
any time of Day 8, 15, 29, 57, 92, 99, 113, 141, and 169. 
6.4 Safety Assessments 
Safety will be assessed by monitoring and recording of Adverse Event (AEs), Serious Adverse 
Event (SAEs), physical examination findings and vital sign measurements (systolic and diastolic 
blood pressures, heart rate, respiratory rate, and oral body temperature), clinical laboratory test 
results (hematology, coagulation, serum chemistry [including liver function tests], and urinalysis), 
and 12-lead ECG results. 
6.4.1 Adverse Events  
The Adverse Event section (Section 7) describes the Adverse Event (SAEs), Serious Adverse 
Event (SAEs) and Adverse Events of Special Interest to be collected during the study. 
6.4.2 Physical Examinations 
A complete physical examination will be performed at the time points indicated in the schedule of 
events. 
A complete physical examination will include assessment of skin (including any signs for 
cutaneous erythema), head, ears, eyes, nose, throat, neck, thyroid, lungs, heart, cardiovascular 
system, abdomen, lymph nodes, and musculoskeletal system/extremities. Interim physical 
examinations will be performed at the discretion of the investigator, if necessary, to evaluate AEs 
or clinical laboratory abnormalities. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
45 
Confidential 
Height and weight will be measured and body mass index will be calculated at screening only. 
Weight will also be measured at all other physical examination time points as indicated in the 
schedules of events for the study. Body weight will be recorded in kilograms (kg) to 1 decimal 
place in indoor clothing (without coat and shoes) and body height (without shoes) will be 
measured in centimeters (cm) without decimal places.  
6.4.3 Vital Sign Measurements 
Vital sign measurements will include systolic and diastolic blood pressures, heart rate, respiratory 
rate, and body temperature. The subject will be seated for at least 5 minutes before all 
measurements are taken. Vital signs will be measured at the time points indicated in the schedule 
of events. 
When procedures are overlapping and occurring at the same time point, the order of procedures 
should be vital sign measurements and then ECGs. 
The investigator will determine whether any of the vital sign measurements are clinically 
significant or not clinically significant. Clinical significance is defined as any variation in results 
that has medical relevance and may result in an alteration in medical care (eg, active observation, 
diagnostic measures, or therapeutic measures). If a clinically significant change from the screening 
values is noted, the clinically significant value and reason for clinical significance will be 
documented in the AE page of the subject’s CRF. The investigator will continue to monitor the 
subject with additional assessments until the value has reached the reference range or the value at 
screening or until the investigator determines that follow-up is no longer medically necessary. 
6.4.4 Clinical Laboratory Testing 
Clinical laboratory tests will be performed by local site. Blood and urine will be collected under 
fasting conditions (fasted for approximately 2 or more hours) at the time points indicated in the 
schedule of events.  
The following hematology, coagulation, serum chemistry (including liver function and thyroid 
function tests), urinalysis assessments will be performed: 
Hematology:
Hematocrit (Hct), hemoglobin (Hb), mean corpuscular hemoglobin (MCH), 
mean corpuscular hemoglobin concentration (MCHC), mean corpuscular 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
46 
Confidential 
volume (MCV), platelet count, red blood cell (RBC) count, and WBC and 
differential count (absolute and percent). 
Coagulation:
International normalized ratio (INR), partial thromboplastin time (PTT), and 
prothrombin time (PT) 
Serum 
Chemistry: 
ALT, albumin, alkaline phosphatase, amylase, anion gap, AST, bicarbonate, 
bilirubin (total and direct), blood urea nitrogen (BUN), calcium, carbon 
dioxide, chloride, cholesterol (total, high-density lipoprotein, and calculated 
low-density 
lipoprotein), 
creatine 
phosphokinase, 
creatinine, 
gamma-glutamyltransferase 
(γ-GT), 
globulin, 
glucose, 
lactate 
dehydrogenase (LDH), lipase, magnesium, phosphorus, potassium, sodium, 
total protein, triglycerides, troponin I or T, and uric acid 
Thyroid 
Function: 
Free T4 and thyroid-stimulating hormone 
Urinalysis: 
Appearance, bilirubin, color, glucose, ketones, leukocyte esterase, 
microscopy (performed if dipstick is positive; includes bacteria, casts, 
crystals, epithelial cells, red blood cells, and white blood cells), nitrites, 
occult blood, pH, protein, specific gravity, turbidity, and urobilinogen 
A serum pregnancy test (β-human chorionic gonadotropin) will be performed on all female 
subjects with potential of children bearing at screening and confirmed result prior to dosing. Urine 
pregnancy tests will be performed on Days 8, 15, 29, 57, 85, 92, 99, 113, 141, and 169. For female 
subjects who are postmenopausal, a serum follicle-stimulating hormone test will be performed at 
screening. 
Hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus 
antibody will be assessed at screening. 
Abnormal clinical laboratory values will be flagged as either high or low (or normal or abnormal) 
based on the reference ranges for each laboratory parameter. The investigator will determine 
whether any of the abnormally high or low results are clinically significant or not clinically 
significant. Clinical significance is defined as any variation in results that has medical relevance 
and may result in an alteration in medical care (eg, active observation, diagnostic measures, or 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
47 
Confidential 
therapeutic measures). If a clinically significant change from the screening value is noted, the 
clinically significant value and reason for clinical significance will be documented in the AE page 
of the CRF. The investigator will continue to monitor the subject with additional assessments until 
the values have reached the reference range or the values at screening or until the investigator 
determines that follow-up is no longer medically necessary. 
Clinically significant laboratory values for individual subjects will be listed. A summary for the 
number and percentage of subjects with clinically significant laboratory values at any time point 
will be presented.  
 
6.4.5 Electrocardiograms 
Single 12-lead ECGs will be obtained after the subject has been in the supine position for at least 
5 minutes at the time points indicated in the schedule of events. Electrocardiogram assessments 
will include comments on whether the tracings are normal or abnormal, rhythm, presence of 
arrhythmia or conduction defects, morphology, any evidence of myocardial infarction, or ST 
segment, T wave, and U wave abnormalities. In addition, measurements of the following intervals 
will be measured and reported: RR interval, PR interval, QRS width, QT interval, and QTcF. 
The investigator will determine whether any of the 12-lead ECG results are clinically significant or 
not clinically significant. Clinical significance is defined as any variation in results that has 
medical relevance and may result in an alteration in medical care (eg, active observation, 
diagnostic measures, or therapeutic measures). If a clinically significant change from screening is 
noted, the clinically significant value and reason for clinical significance will be documented in the 
AE page of the subject’s CRF. The investigator will continue to monitor the subject with additional 
assessments until either the values have reached reference range or the values at screening or until 
the investigator determines that follow-up is no longer medically necessary. 
6.5 Other Assessments 
6.5.1 Informed Consent and Subject Identification  
Before performing any study procedures, all potential subjects will sign an informed consent form 
(ICF). The investigator must address all questions raised by the subject before the subject signs the 
consent form. The investigator will also sign the ICF.  


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
48 
Confidential 
6.5.2 Screening and Subject Number 
A subject enter the study will be assigned a screening number.  Subject when confirmed eligible 
will be assigned a subject number and this subject number will be used throughout the study.  
6.5.3 Demographic Data  
Demographic data including date of birth, gender and race will be collected in the CRF at 
screening (day -28 to -1).  
6.5.4 
Medical History and Concomitant Medications 
A complete medical and medication history for the subjects will be collected in the CRF at 
screening (Day -28 to -1). Whenever possible, diagnoses but not symptoms should be recorded. 
Any medical conditions developing during the screening period and any treatment taken from Day 
-28 to -1 will be recorded in the medical history section in CRF. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
49 
Confidential 
6.6 Schedule of events  
Subjects will undergo study procedures at the time points specified in the schedule of events. 
Table 6.5-1 
Schedule of Events 
Procedure 
Screening 
Dose 1 FB825 
Dose 2 FB825 
Study Day(s) 
−28 to −1 
Day 1 a 
Day 2 
Day 8 
Day 15 
Day 29 
Day 57 
Day 85 a 
Day 86 
Day 92 
Day 99 
Day 113 Day 141 
Day 
169/EOSb 
(±1) 
(±1) 
(±2) 
(±2) 
(±3) 
(±1) 
(±1) 
(±2) 
(±2) 
(±3) 
Informed consent 
X 
  
  
  
  
  
  
  
  
  
  
  
    
Inclusion 
/Exclusion criteria 
X 
X 
  
  
  
  
  
  
  
  
  
  
  
 
Medical history 
X 
  
  
  
  
  
  
  
  
  
  
  
  
Physical 
examination 
X 
X 
  
X 
X 
X 
X 
X 
  
X 
X 
X 
X 
X 
Vital sign 
measurements c, d 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
12-Lead 
electrocardiogram 
e 
X 
X 
X 
X 
X 
X 
  
X 
X 
X 
X 
X 
  
X 
AD symptom 
evaluation f 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serology g 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
50 
Confidential 
Clinical 
laboratory testing 
h 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Thyroid function 
testing 
X 
X 
  
  
X 
X 
  
X 
  
  
X 
X 
  
X 
Urine drug, and 
blood alcohol test  
 X 
Xm 
  
  
  
  
  
X 
  
  
  
  
 
X 
Pregnancy test 
(female subjects) i 
X 
X 
  
X 
X 
X 
X 
X 
  
X 
X 
X 
X 
X 
Serum FSH j 
X 
 
  
  
  
  
  
  
  
  
  
  
 
  
Admission to 
clinic 
 
X 
  
  
  
  
  
X 
  
  
  
  
 
  
Study drug IV 
administration 
 
X 
  
  
  
  
  
X 
  
  
  
  
 
  
Total 
Immunoglobulin/ 
Allergen-specific 
IgE k 
X 
X 
  
X 
X 
X 
X 
X 
  
X 
X 
X 
X 
X 
Biomarker 
Assessmentsl 
  
X 
  
X 
X 
X 
X 
X 
  
X 
X 
X 
X 
X 
Adverse events 
assessment 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Prior/Concomitant 
medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Discharge from 
  
  
X 
  
  
  
  
  
X 
  
  
    
  


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
51 
Confidential 
clinic 
 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; EOS, end of study; FSH, follicle-stimulating hormone; Ig, immunoglobulin. 
a. 
Subjects will check into the clinic on Day 1 and Day 85 and have check-in procedures performed. 
b. 
Subjects early withdraw from the study will be requested to have an EOS visit and perform required activities. 
c. 
Vital sign measurements (systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature) will be obtained at screening; Day 1, and  
85 before the start of infusion and all study visits. Vital sign measurements will be obtained at 1.25 (end of infusion), 2, 4, 8 hours (± 5 minutes in each time 
points) after the start of the infusion on Day 1, and  Day 85,and prior to discharge on Day 2 and Day 86. During the infusion, vital sign measurements will be 
obtained every 15 minutes (± 5 minutes). 
d. 
When procedures are overlapping and occurring at the same time point, the order of procedures should be vital sign measurements and then ECGs. 
e. 
Twelve-lead electrocardiograms will be obtained at screening; on Day 1 and Day 85 within 2 hours before the start of infusion and at 1.25 (end of infusion, ± 
5 minutes), 8 hours (± 5 minutes) after the start of the infusion; prior to discharge; and all other study visits, except Day 57, and 141. 
f. 
AD symptom evaluation is determined by VAS, EASI, SCORAD, IGA, and BSA. These are evaluated by Investigator at screening; on Day 1 prior to dosing, 
and all other study visits. 
g. 
Serology testing will include hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus antibodies. 
h. 
Clinical laboratory tests (hematology, coagulation, serum chemistry [including liver function tests and glucose test], and urinalysis) will be performed at 
screening; on Day 1 and Day 85 before the start of infusion and at 1.25 (end of infusion, ± 5 minutes), 8 hours (± 5 minutes) after the start of the infusion; prior 
to discharge, and all other study visits. 
i. 
A serum pregnancy test will be performed for females of childbearing potential only at screening and at the end-of-study visit. Urine pregnancy tests will be 
performed on all other study visits, in Day 1 only to confirm the results, no need to have a test again. 
j. 
Female subjects who are postmenopausal will have a serum FSH test at screening. 
k. 
Blood samples for the measurement of total immunoglobulin/ Allergen-specific immunoglobulin E will be collected at screening, on Day 1 and 85 (in 2 hours  
before the start of infusion); and on all other study visits. 
l. 
Blood samples for the measurement of biomarkers including thymus and activation regulated chemokine (TARC), Eotaxin-3, thymic stromal lymphopoietin 
(TSLP), periostin, IL-1 , IL-4, IL-5, IL-13, IL-16, IL-31 and M-CSF will be collected at Day 1 and 85 (in 2 hours before the start of infusion), and on Days 8, 
15, 29, 57, 92, 99, 113, and 141. 
m. 
The X in Day 1 of Urine drug and blood alcohol test means to confirm the results, no need to have a test again. 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
52 
Confidential 
7 Adverse Events 
The investigator is responsible for reporting all AEs that are observed or reported during the study, 
regardless of their relationship to study drug or their clinical significance. If there is any doubt as to 
whether a clinical observation is an AE, the event should be reported. 
7.1 Definitions 
7.1.1 Adverse Event (AE)  
An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. Subjects will be instructed to contact the investigator at 
any time during the study period if any symptoms develop. 
A TEAE is defined as any event not present before exposure to study drug or any event already 
present that worsens in intensity or frequency after exposure. 
An adverse reaction is any AE caused by a drug. Adverse reactions are a subset of all suspected 
adverse reactions for which there are reasons to conclude that the drug caused the event. 
A suspected adverse reaction is any AE for which there is a reasonable possibility that the study 
drug caused the AE. For the purposes of investigational new drug safety reporting, “reasonable 
possibility” means that there is evidence to suggest a causal relationship between the study drug 
and the AE. A suspected adverse reaction implies a lesser degree of certainty about causality than 
adverse reaction, which means any AE caused by a study drug. 
An AE or suspected adverse reaction is considered “unexpected” if it is not listed in the IB or at the 
specificity or severity that has been observed with the study drug being tested; or, if an IB is not 
required or available, is not consistent with the risk information described in the general 
investigational plan or elsewhere in the current application. For example, under this definition, 
hepatic necrosis would be unexpected (by virtue of greater severity) if the IB referred only to 
elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral 
vasculitis would be unexpected (by virtue of greater specificity) if the IB listed only cerebral 
vascular accidents. "Unexpected," as used in this definition, also refers to AEs or suspected 
adverse reactions that are mentioned in the IB as occurring with a class of drugs or as anticipated 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
53 
Confidential 
from the pharmacological properties of the drug, but are not specifically mentioned as occurring 
with the particular drug under investigation. 
7.1.2 Serious Adverse Event (SAE)  
An AE or suspected adverse reaction is considered an SAE if, in the view of either the investigator 
or sponsor, it results in any of the following outcomes: 
• Death 
• Life-threatening AE 
• Inpatient hospitalization or prolongation of existing hospitalization 
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions 
• Congenital anomaly or birth defect 
Important medical events that may not result in death, be life threatening, or require hospitalization 
may be considered serious when, based upon appropriate medical judgment, they may jeopardize 
the subject and may require medical or surgical intervention to prevent one of the outcomes listed 
in this definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
An AE or suspected adverse reaction is considered “life threatening” if, in the view of either the 
investigator or sponsor, its occurrence places the subject at immediate risk of death. It does not 
include an AE or suspected adverse reaction that, had it occurred in a more severe form, might 
have caused death. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
54 
Confidential 
7.1.3 Adverse Events of Special Interest 
Adverse events of special interest include the following events:  
1. Any subject experiences a treatment-emergent AE (TEAE) of anaphylaxis 
2. Any subject experiences an SAE (Section 7.1.2) 
3. Any subject experiences a persistent QT prolongation (>500 milliseconds, or ≥60 milliseconds 
change from baseline) for at least 30 minutes or ischemic changes on repeated ECGs, or 
persistent symptomatic arrhythmia 
4. Hypersensitivity reactions including anaphylaxis, thyroid abnormalities, cutaneous erythema, 
thrombocytopenia, anemia, hemolysis, neutropenia, hepatotoxicity, and nephrotoxicity 
5. The following laboratory parameters are encountered in any individual subject: 
• ALT or AST ≥5 × ULN 
• Bilirubin ≥2 × ULN 
• Platelet count grade 1 ≤99.999*109/L 
• Hemoglobin ≤105 g/L 
• Absolute neutrophil count grade 1 ≤1.5*109/L 
• Blood urea nitrogen or creatinine rise to >2 × ULN 
7.2 Eliciting of Adverse Events 
The investigator is responsible for ensuring that all AEs and SAEs are recorded in the CRF and 
reported to Fountain. Adverse events will be assessed from the time of screening period until 
completion of all study procedures and discharge from the study. 
At every study visit or assessment, subjects will be asked a standard question to elicit any 
medically-related changes in their well-being. They will also be asked if they have been 
hospitalized, had any accidents, used any new medications, or changed concomitant medication 
regimens (both prescription and over-the-counter medications). 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
55 
Confidential 
In addition to subject observations, AEs will be documented from any data collected in the AE 
page of the CRF (eg, laboratory values, physical examination findings, and ECG changes) or other 
documents that are relevant to subject safety. 
7.3 Documenting Adverse Events 
All AEs reported or observed during the study will be recorded in the AE page of the CRF. 
Information to be collected includes drug treatment, type of event, time of onset, dosage, 
investigator-specified assessment of severity and relationship to study drug, time of resolution of 
the event, seriousness, as well as any required treatment or evaluations, and outcome. The AEs 
resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent 
medications, or progression of disease states must also be reported. All AEs will be followed until 
they are resolved or stable or judged by the investigator to be not clinically significant. The 
Medical Dictionary of Regulatory Activities (MedDRA) will be used to code all AEs. 
Any medical condition that is present at the time that the subject is screened but does not 
deteriorate should not be reported as an AE. However, if it deteriorates at any time during the 
study, it should be recorded as an AE. 
7.3.1 Assessment of Severity 
The severity (or intensity) of an AE using the Common Terminology Criteria for Adverse Events 
(CTCAE) will be used for infusion reaction severity grading. 
• Grade 1 Mild: Transient or mild discomfort (<48 hours); no medical intervention/therapy 
required. 
• Grade 2 Moderate: Mild to moderate limitation in activity - some assistance may be needed; no 
or minimal medical intervention/therapy required. 
• Grade 3 Severe: Marked limitation in activity, some assistance usually required; medical 
intervention/therapy required, hospitalization possible. 
• Grade 4 Life threatening: Extreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, hospitalization or hospice care probable. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
56 
Confidential 
Changes in the severity of an AE should be documented to allow an assessment of the duration of 
the event at each level of intensity to be performed. An AE characterized as intermittent requires 
documentation of onset and duration of each episode. 
7.3.2 Assessment of Causality 
The investigator’s assessment of an AE’s relationship to study drug is part of the documentation 
process but is not a factor in determining what is or is not reported in the study. 
The investigator will assess causality (ie, whether there is a reasonable possibility that the study 
drug caused the event) for all AEs and SAEs. The relationship will be characterized using the 
following classification: 
• Unrelated: This relationship suggests that there is no association between the study drug and 
the reported event. 
• Possible: This relationship is based on evidence suggesting a causal relationship between the 
study drug and the AE, ie, there is a reasonable possibility that the drug caused the event. The 
event follows a reasonable temporal sequence from the time of drug IV administration or 
follows a known response pattern to the study drug, but could also have been produced by 
other factors. 
• Probable: This relationship suggests that a reasonable temporal sequence of the event with 
drug IV administration exists and, based upon the known pharmacological action of the drug, 
known or previously reported adverse reactions to the drug or class of drugs, or judgment 
based on the investigator’s clinical experience, the association of the event with the study drug 
seems likely. 
• Definite: This relationship suggests that a definite causal relationship exists between drug IV 
administration and the AE, and other conditions (concurrent illness, progression/expression of 
disease state, or concurrent medication reaction) do not appear to explain the event. 
7.3.3 Follow-up of Adverse Events 
All AEs must be reported in detail in the appropriate page of the CRF and followed until they are 
resolved or stable or judged by the investigator to be not clinically significant. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
57 
Confidential 
7.4 Reporting Serious Adverse Events 
Any AE considered serious by the investigator or that meets SAE criteria (Section 7.1.2) must be 
reported to the sponsor immediately (after the investigator has confirmed the occurrence of the 
SAE). The investigator will assess whether there is a reasonable possibility that the study drug 
caused the SAE. The sponsor will be responsible for notifying the relevant regulatory authorities 
of any SAE as outlined in the ICH Guideline for Good Clinical Practice (GCP) and the National 
Statement on Ethical Conduct in Research Involving Humans 2007. The investigator is 
responsible for notifying the IRB/EC directly. 
Information regarding serious adverse events will be transmitted to the sponsor using the Serious 
Adverse Event Form, which must be signed by investigator. The initial report of a serious adverse 
event may be made by facsimile (fax) or telephone. It is preferable that serious adverse events be 
reported via fax. A telephone report of a serious adverse event must be followed by a completed 
Serious Adverse Event Form from the investigator. 
In addition, the suspected unexpected serious adverse reactions (SUSAR) should also forward to 
IRB and health authority by the sponsor within the time frame according to the regulation of the 
health authority. 
 
 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
58 
Confidential 
8 Statistical Analysis 
8.1 General Statistics 
Details of all statistical analyses will be described in a statistical analysis plan. All data collected 
will be presented in data listings. Data from subjects excluded from an analysis population will be 
presented in the data listings but not included in the calculation of summary statistics. 
For categorical variables, frequencies and percentages will be presented. Continuous variables will 
be summarized using descriptive statistics (number of subjects, mean, median, SD, minimum, and 
maximum). 
Baseline demographic and background variables will be summarized by dose and overall for all 
subjects. The number of subjects who enroll in the study and the number and percentage of 
subjects who complete the study will be presented. Frequency and percentage of subjects who 
withdraw or discontinue from the study, and the reason for withdrawal or discontinuation, will also 
be summarized. Analysis for this study will be demonstrated with descriptive statistics for each 
period and group. No significance test will be applied. 
A statistical analysis plan (SAP) will be written to address statistical analysis work in detail. The 
clinical database lock will occur after all data are reconciled (i.e., “cleaned”) after the last patient 
completes the study. 
8.2 Sample Size Calculations 
A total of approximately 12 evaluable subjects are planned for this study. The sample size for this 
study is based on clinical and practical considerations and not on a formal statistical power 
calculation. 
8.3 Analysis Sets 
Full Analysis Set (FAS) is defined as subjects who received at least 1 dose of study drug. All 
efficacy evaluation will be performed in FAS population. 
The Safety population is defined as subjects who received at least 1 dose of study drug. All safety 
evaluation will be performed in safety population. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
59 
Confidential 
8.4 Statistical Analysis 
8.4.1 Biomarker Analyses 
Concentration and change from baseline in total and allergen-specific IgE and biomarkers listed as 
endpoints will be summarized by visit and presented graphically. Change from baseline in total 
and allergen-specific IgE will also be summarized by the baseline total IgE concentration (serum 
IgE>1500IU/mL or serum IgE ≤1500IU/mL) and given FB825 doses (1 dose or 2 doses).  
In subjects who receive the second dose of FB825, the data collected for the second dose will be 
analysis and summarized as same as those collected for the first dose.  
8.4.2 Clinical Efficacy Analysis 
The evaluation index will be assessed by PI or co-PI during every visit for each subject. The 
clinical endpoints will be analyzed using descriptive statistic (mean of EASI, SCORAD, IGA, 
VAS, and BSA; SD, CV, number of subjects) by visit time points and given FB825 doses (1 dose 
or 2 doses). 
The change of mean index versus scheduled visit time profiles will be presented graphically 
In subjects who receive the second dose of FB825, the data collected for the second dose will be 
analysis and summarized as same as those collected for the first dose. 
8.4.3 Safety Analyses 
Adverse events will be coded by preferred term and system organ class using the latest version of 
the Medical Dictionary for Regulatory Activities and summarized by treatment, dose level, and 
overall. Adverse events will also be summarized by severity, relationship to study drug, SAEs, and 
AEs leading to discontinuation of study drug. 
Actual values and changes from baseline for clinical laboratory test results, vital sign 
measurements, and 12-lead ECG results will be summarized by treatment and dose at each time 
point using descriptive statistics (number of subjects, mean, SD, median, minimum, and 
maximum). Shift tables will be generated for clinical laboratory test results. Clinical laboratory 
data, vital sign measurements, 12-lead ECG results, and physical examination findings will be 
presented in data listings. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
60 
Confidential 
8.5 Handling of Missing Data 
Concentrations that are below the limit of quantification (BLQ) will be treated as zero for 
descriptive statistics. Mean BLQ concentrations will be presented as BLQ, and the SD and CV will 
be reported as not applicable. Missing concentrations will be excluded from the calculations. 
Last observation carry forward (LOCF) will be applied to handle missing data. No imputation will 
be available for safety data. 
8.6  Interim Analyses 
No interim analysis is planned. 
8.7 Data Quality Assurance 
All aspects of the study will be monitored for compliance with applicable government regulations 
with respect to current International Conference on Harmonisation (ICH) harmonised tripartite 
guideline E6 (R1): Good Clinical Practice and current standard operating procedures. There may 
be an internal quality review audit of the data and additional reviews by the clinical monitor. 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
61 
Confidential 
9 Investigator Obligations 
The following administrative items are meant to guide the investigator in the conduct of the study 
and may be subject to change based on industry and government standard operating procedures, 
working practice documents, or guidelines. Changes will be reported to the IRB/EC but will not 
result in protocol amendments. 
9.1 Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records will be identified in a 
manner designed to maintain subject confidentiality. All records will be kept in a secure storage 
area with limited access. Clinical information will not be released without the written permission 
of the subject (or the subject’s legal guardian), except as necessary for monitoring and auditing by 
the sponsor, its designee, regulatory authorities such as the FDA, or the IRB/EC. 
The investigator and all employees and coworkers involved with this study may not disclose or use 
for any purpose other than performance of the study, any data, record, or other unpublished, 
confidential information disclosed to those individuals for the purpose of the study. Prior written 
agreement from the sponsor or its designee must be obtained for the disclosure of any said 
confidential information to other parties. 
9.2 Institutional Review 
ICH E6 (R1) guidelines and applicable regulatory requirements require that approval be obtained 
from an IRB/EC before participation of human subjects in research studies. Before study onset, the 
protocol, informed consent, advertisements to be used for the recruitment of study subjects, and 
any other written information regarding this study to be provided to the subject or the subject’s 
legal guardian must receive written approval by each IRB/EC. Documentation of all IRB/EC 
approvals and of the IRB/EC compliance with the ICH E6 (R1) guidelines will be maintained by 
the site and will be available for review by the sponsor or its designee. 
All IRB/EC approvals should be signed by the IRB/EC chairman or designee and must identify the 
IRB/EC name and address, the clinical protocol by title or protocol number or both and the date 
approval or a favorable opinion was granted. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
62 
Confidential 
9.3 Subject Consent 
Written informed consent in compliance with ICH E6 (R1) guidelines and applicable regulatory 
requirements shall be obtained from each subject before he or she enters the study or before any 
unusual or nonroutine procedure that involves risk to the subject is performed. If any 
institution-specific modifications to study-related procedures are proposed or made by the site, the 
consent should be reviewed by the sponsor or its designee or both before IRB/EC submission. 
Once reviewed, the investigator will submit the ICF to the IRB/EC for review and approval before 
the start of the study. If the ICF is revised during the course of the study, all active participating 
subjects must sign the revised form. 
Before recruitment and enrollment, each prospective subject or his or her legal guardian will be 
given a full explanation of the study and be allowed to read the approved ICF. Once the 
investigator is assured that the subject/legal guardian understands the implications of participating 
in the study, the subject/legal guardian will be asked to give his or her consent to participate in the 
study by signing the ICF. 
The investigator will provide a copy of the signed ICF to the subject or legal guardian. An original 
signed ICF shall be maintained in the subject’s medical records at the site. 
9.4 Study Reporting Requirements 
By participating in this study, the investigator agrees to submit reports of SAEs according to the 
time line and method outlined in this protocol. In addition, the investigator agrees to submit annual 
reports to his or her IRB/EC as appropriate. 
9.5 Financial Disclosure and Obligations 
The investigator is required to provide financial disclosure information to allow the sponsor to 
submit the complete and accurate certification or disclosure statements. In addition, the 
investigator must provide to the sponsor a commitment to promptly update this information if any 
relevant changes occur during the course of the investigation and for 1 year following the 
completion of the study. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
63 
Confidential 
9.6 Investigator Documentation 
Prior to beginning the study, the investigator will be asked to comply with ICH E6 (R1) 8.2 by 
providing the following essential documents, including but not limited to: 
IRB/EC approval, 
An original investigator-signed investigator agreement page of the protocol, 
Form FDA 1572, fully executed, and all updates on a new fully executed Form FDA 1572, 
Curriculum vitae for the principal investigator and each subinvestigator listed on Form FDA 1572. 
Current licensure must be noted on the curriculum vitae. They will be signed and dated by the 
principal investigators and subinvestigators at study start-up, indicating that they are accurate and 
current, 
Financial disclosure information to allow the sponsor to submit complete and accurate 
certification or disclosure statements. In addition, the investigators must provide to the sponsor a 
commitment to promptly update this information if any relevant changes occur during the course 
of the investigation and for 1 year after the completion of the study, 
An IRB/EC-approved ICF, samples of site advertisements for recruitment for this study, and any 
other written information about this study that is to be provided to the subject or legal guardians, 
and 
Laboratory certifications and reference ranges for any local laboratories used by the site. 
9.7 Study Conduct 
The investigator agrees that the study will be conducted according to the principles of ICH E6 
(R1). The investigator will conduct all aspects of this study in accordance with all national, state, 
and local laws or regulations. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
64 
Confidential 
9.8 Data Collection 
9.8.1 
Case Report Forms and Source Documents 
The study site will maintain source documentation and enter subject data into the CRF as 
accurately as possible and will respond to any reported discrepancies rapidly. 
Electronic CRFs will be utilized and accessed through an electronic data capture (EDC) system. 
This electronic data capture system is validated and compliant with 21 Code of Federal 
Regulations 11. Each person involved with the study will have an individual identification code 
and password that allows for record traceability. Thus, the system, and subsequently any 
investigative reviews, can identify coordinators, investigators, and individuals who have entered 
or modified records, as well as the time and date of any modifications. There is an internal quality 
review audit of the data and additional reviews by the clinical monitor. 
Each eCRF is presented as an electronic copy, allowing data entry by site personnel, who can add 
and edit data, add new subjects, identify and resolve discrepancies, and view records. This system 
provides immediate direct data transfer to the database, as well as immediate detection of 
discrepancies, enabling site coordinators to resolve and manage discrepancies in a timely manner. 
Paper copies of the eCRFs and other database reports may be printed and signed by the 
investigator. This system provides site personnel, monitors, and reviewers with access to hardcopy 
audits, discrepancy reviews, and investigator comment information. 
9.9 Adherence to Protocol 
The investigator agrees to conduct the study as outlined in this protocol in accordance with ICH E6 
(R1) and all applicable guidelines and regulations. 
9.10 Reporting Adverse Events 
By participating in this study the investigator agrees to submit reports of SAEs according to the 
time line and method outlined in this protocol. In addition, the investigator agrees to submit annual 
reports to his or her IRB/EC as appropriate. The investigator also agrees to provide the sponsor 
with an adequate report, if applicable, shortly after completion of the investigator’s participation in 
the study. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
65 
Confidential 
9.11 Investigator’s Final Report 
Upon completion of the study, the investigator, where applicable, should inform the institution; the 
investigator/institution should provide the IRB/EC with a summary of the study’s outcome and the 
sponsor and regulatory authority(ies) with any reports required. 
9.12 Records Retention 
Essential documents should be retained until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of 
clinical development of the study drug. These documents should be retained for a longer period, 
however, if required by the applicable regulatory requirements or by an agreement with the 
sponsor. It is the sponsor’s responsibility to inform the investigator/institution as to when these 
documents no longer need to be retained. 
9.13 Publications 
After completion of the study, the data may be considered for reporting at a scientific meeting or 
for publication in a scientific journal. In these cases, the sponsor will be responsible for these 
activities and will work with the investigators to determine how the manuscript is written and 
edited, the number and order of authors, the publication to which it will be submitted, and other 
related issues. The sponsor has final approval authority over all such issues. 
Data are the property of the sponsor and cannot be published without their prior authorization, but 
data and publication thereof will not be unduly withheld. 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
66 
Confidential 
10 Study Management 
10.1 Monitoring 
10.1.1 Monitoring of the Study 
The clinical monitor, as a representative of the sponsor, is obligated to follow the study closely. In 
doing so, the monitor will visit the investigator and study facility at periodic intervals, in addition 
to maintaining necessary telephone and letter contact. The monitor will maintain current personal 
knowledge of the study through observation, review of study records and source documentation, 
and discussion of the conduct of the study with the investigator and staff. 
All aspects of the study will be carefully monitored by the sponsor or its designee for compliance 
with applicable government regulation with respect to current ICH E6 (R1) guidelines and 
standard operating procedures. 
10.1.2 Inspection of Records 
The investigator and institution involved in the study will permit study-related monitoring, audits, 
IRB/EC review, and regulatory inspections by providing direct access to all study records. In the 
event of an audit, the investigator agrees to allow the sponsor, their representatives, the FDA, or 
other regulatory agency access to all study records. 
The investigator should promptly notify the sponsor of any audits scheduled by any regulatory 
authorities and promptly forward copies of any audit reports received to the sponsor. 
10.2 Management of Protocol Amendments and Deviations 
10.2.1 Modification of the Protocol 
Any changes in this research activity, except those necessary to remove an apparent, immediate 
hazard to the subject, must be reviewed and approved by the sponsor or designee. Amendments to 
the protocol must be submitted in writing to the investigator’s IRB/EC and receive approval before 
subjects are enrolled by an amended protocol. 
10.2.2 Protocol Violations and Deviations 
The investigator or designee must document and explain in the subject’s source documentation any 
deviation from the approved protocol. The investigator may implement a deviation from, or a 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
67 
Confidential 
change to, the protocol to eliminate an immediate hazard to study subjects without prior IRB/EC 
approval. As soon as possible after such an occurrence, the implemented deviation or change, the 
reasons for it, and any proposed protocol amendments should be submitted to the IRB/EC for 
review and approval, to the sponsor for agreement, and to the regulatory authorities, if required. 
A deviation from the protocol is an unintended or unanticipated departure from the procedures or 
processes approved by the sponsor and the IRB/EC and agreed to by the investigator. Deviations 
usually have an impact on individual subjects or a small group of subjects and do not involve 
inclusion/exclusion or primary endpoint criteria. A protocol violation occurs when the subject or 
investigator does not adhere to the protocol, resulting in a significant, additional risk to the subject. 
Protocol violations can include nonadherence to inclusion or exclusion criteria, enrollment of the 
subject without prior sponsor approval, or nonadherence to local regulations or ICH E6 (R1) 
guidelines. 
Protocol violations and deviations will be documented by the clinical monitor throughout the 
course of monitoring visits. The investigator will be notified in writing by the monitor of violations 
and deviations. The IRB/EC should be notified of all protocol violations and deviations, if 
appropriate, in a timely manner. 
10.3 Study Termination 
Although the sponsor has every intention of completing the study, they reserve the right to 
discontinue it at any time for clinical or administrative reasons. 
The end of the study is defined as the date on which the last subject completes the last visit 
(includes the end-of-study visit and any additional long-term follow-up). Any additional long-term 
follow-up that is required to monitor the resolution of a finding or AE may be reported through an 
amendment to the clinical study report. 
10.4 Final Report 
Whether the study is completed or prematurely terminated, the sponsor will ensure that clinical 
study reports are prepared and provided to the regulatory agency(ies) as required by the applicable 
regulatory requirement(s). The sponsor will also ensure that clinical study reports in marketing 
applications meet the standards of the ICH harmonised tripartite guideline E3: Structure and 
content of clinical study reports. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
68 
Confidential 
Where required by applicable regulatory requirements, an investigator signatory will be identified 
for the approval of the clinical study report. The investigator will be provided reasonable access to 
statistical tables, figures, and relevant reports and have the opportunity to review complete study 
results. 
Upon completion of the clinical study report, the sponsor will provide the investigator(s) with the 
final approved clinical study report. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
69 
Confidential 
11 Reference List 
Chan YH. Evaluation of FB825 apoptotic activity on mIgE+ B cells. Report 
No. FB825-20120320-35-1. Fountain Biopharma Nonclinical Report (10 Apr 2012). 
Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18: 157–
62Chang TW. Developing antibodies for targeting immunoglobulin and membrane-bound 
immunoglobulin E. Allergy Asthma Proc. 2006;27:S7-14. 
Chang TW, Wu PC, Hsu CL, et al. Anti-IgE antibodies for the treatment of IgE-mediated allergic 
diseases. Adv Immunol. 2007;93:63-119. 
Chen JB, Wu PC, Hung AF, et al. Unique epitopes on CεmX in IgE-B cell receptors are potentially 
applicable for targeting IgE committed B cells. J Immunol. 2010;184:1748-56. 
Cheng TT. Evaluation of FB825 on antibody-dependent cell cytotoxicity. Report 
No. FB825-20140618-11-1. Fountain Biopharma Nonclinical Report (27 Jun 2014). 
Chou HW, Li S, Weng A. Evaluation of FB825 IgE production inhibition (II): engrafting human 
PBMCs into NOD-SCID mice. Report No. FB825-20111017-19-1. Fountain Biopharma 
Nonclinical Report (06 Jun 2013). 
Department of Health and Human Services, Food and Drug Administration, Center for Drug 
Evaluation and Research (US). Guidance for industry: Estimating the maximum safe starting dose 
in initial clinical trials for therapeutics in adult healthy volunteers. July 2005 [cited 2014 Aug 17] 
[30 
screens]. 
Available 
from: 
http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf CachedSimilar. 
Fountain BioPharma Inc. FB825. Investigator’s brochure. Taipei (Taiwan); 2014. 
Gauvreau GM, Harris JM, Boulet LP, et al. Targeting membrane-expressed IgE B-cell receptor 
with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med. 2014; 6:1-10. 
Hatakeyama H, Takei Y, Cruz Y, et al. Spontaneous vacuolar degeneration of the thyroid follicular 
epithelium in cynomolgus monkeys. J Toxicol Pathol. 2011;24(4):229-32. 
Ishida K, Narita K, Ito K, et al. Morphologic variations in the thyroid glands of cynomolgus 
monkeys (macaca fascicularis). J Toxicol Pathol. 2000;13:189-91. 
Li S, Liour S. Evaluation of FB825 IgE production inhibition (I): in-vitro isotype-switching of B 
cells isolated from patients with atopic dermatitis. Report No. FB825-20120529-30-1. Fountain 
Biopharma Nonclinical Report (31 Jan 2013). 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
70 
Confidential 
Peng C, Davis FM, Sun LK, et al. A new isoform of human membrane-bound IgE. J Immunol. 
1992;148:129-36. 
Vichyanond P. Omalizumab in allergic diseases, a recent review. Asian Pac J Allergy Immunol. 
2011;29(3):209-19. 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
71 
Confidential 
12 Appendices 
12.1 Appendix 1: National Cancer Institute Common Terminology Criteria for 
Adverse Events v4.03 
The National Cancer Institute Common Terminology Criteria for Adverse Events v4.03 can be 
accessed at the following website link: 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. 
 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
72 
Confidential 
12.2 Appendix 2: Second symposium on the definition and management of 
anaphylaxis: Summary report—Second National Institute of Allergy and 
Infectious Disease/Food Allergy and Anaphylaxis Network symposium 
Second symposium on the definition and management of anaphylaxis: Summary report-Second 
National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
symposium can be accessed at the following website link: 
https://www.google.com/url?url=https://wao.confex.com/wao/wisc12/webprogram/Handout/Pap
er4600/2nd%2520Anaphylaxis%2520Symposium-JACI-02-06.pdf&rct=j&frm=1&q=&esrc=s&
sa=U&ei=pRt2VL2TJ4uZNoG9gGA&ved=0CB8QFjAC&usg=AFQjCNExbzj-VOSsAgnLsLq0
VAXG-aV8gA 
 
Clinical criteria for diagnosing anaphylaxis are presented in Table 12.2–1. 
Table 12.2-1 
Clinical Criteria for Diagnosing Anaphylaxis 
Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (eg, 
generalized hives, pruritus or flushing, swollen lips-tongue-uvula) 
 
AND AT LEAST ONE OF THE FOLLOWING: 
a. 
Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia) 
b. Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia [collapse], syncope, 
incontinence) 
 
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes to 
several hours): 
a. 
Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lips-tongue-uvula) 
b. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia) 
c. 
Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, incontinence) 
d. Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting) 
 
3. Reduced BP after exposure to known allergen for that patient (minutes to several hours): 
a. 
Infants and children: low systolic BP (age specific) or greater than 30% decrease in systolic BP1 
b. Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from that person’s baseline 
Abbreviations: PEF, peak expiratory flow; BP, blood pressure. 
Low systolic blood pressure for children is defined as less than 70 mm Hg from 1 month to 1 year, less than (70 mm Hg + [2 × age]) 
from 1 to 10 years, and less than 90 mm Hg from 11 to 17 years. 
 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
73 
Confidential 
12.3 Appendix 3: Division of Microbiology and Infectious Disease (DMID) 
Adult Toxicity Table November 2007 Draft (For Screening) 
 
 
Grade 1  
Grade 2  
Grade 3  
Grade 4  
HEMATOLOGY  
Hemoglobin  
9.5 - 10.5 gm/dL  
8.0 - 9.4gm/dL  
6.5 - 7.9 gm/dL  
< 6.5 gm/dL  
Platelets  
75,000-99,999/m
m3  
50,000-74,999/m
m3  
20,000-49,999/m
m3  
<20,000/mm
3  
WBCs  
11,000-13,000/ 
mm3  
13,000- 15,000 
/mm3  
15,000- 
30,000/mm3  
>30,000 or 
<1,000 /mm3 
Prothrombin 
Time (PT)  
1.01 - 1.25 x ULN 1.26-1.5 x ULN  
1.51 -3.0 x ULN  
>3 x ULN  
Activated 
Partial 
Thromboplastin 
(APPT)  
1.01 -1.66 x ULN 
1.67 - 2.33 x ULN 2.34 - 3 x ULN  
> 3 x ULN  
CHEMISTRIES  
Hyponatremia  
130-135 mEq/L  
123-129 mEq/L  
116-122 mEq/L  
< 116 mEq/L 
or abnormal 
sodium with 
mental status 
changes or 
seizures  
Hypernatremia 
146-150 mEq/L  
151-157 mEq/L  
158-165 mEq/L  
> 165 mEq/L 
or abnormal 
sodium with 
mental status 
changes or 
seizures  
Hypokalemia  
3.0 - 3.4 mEq/L  
2.5 - 2.9 mEq/L  
2.0 - 2.4 mEq/L or 
intensive 
replacement 
therapy or 
hospitalization 
required  
< 2.0 mEq/L 
or abnormal 
potassiumwit
h paresis, 
ileus or 
life-threateni
ng 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
74 
Confidential 
 
Grade 1  
Grade 2  
Grade 3  
Grade 4  
arrhythmia  
Hyperkalemia  
5.6 - 6.0 mEq/L  
6.1 - 6.5 mEq/L  
6.6 - 7.0 mEq/l  
> 7.0 mEq/L 
or abnormal 
potassium 
with 
life-threateni
ng 
arrhythmia  
Hypoglycemia  
55-64 mg/dL  
40-54 mg/dL  
30-39 mg/dL  
<30 mg/dL or 
abnormal 
glucose with 
mental status 
changes or 
coma  
Hyperglycemia 
(nonfasting and 
no prior 
diabetes)  
116 - 160 mg/dL  
161- 250 mg/dL  
251 - 500 mg/dL  
> 500 mg/dL 
or abnormal 
glucose with 
ketoacidosis 
or seizures  
Hypocalcemia 
(corrected for 
albumin)  
8.4 - 7.8 mg/dL  
7.7 - 7.0 mg/dL  
6.9 - 6.1 mg/dL  
< 6.1 mg/dL 
or abnormal 
calcium with 
life 
threatening 
arrhythmia or 
tetany 
Hypercalcemia 
(correct for 
albumin)  
10.6 - 11.5 mg/dL 11.6 - 12.5 mg/dL 12.6 - 13.5 mg/dL > 13.5 mg/dL 
or abnormal 
calcium with 
life 
threatening 
arrhythmia  
Hypomagnesem
ia  
1.4 - 1.2 mEq/L  
1.1 - 0.9 mEq/L  
0.8 - 0.6 mEq/L  
< 0.6 mEq/L 
or abnormal 
magnesium 
with 
life-threateni
ng 


Clinical Study Protocol: FB825CLIIS-01-AD 
Fountain BioPharma Inc 
 
V1.3 Final, 02-March-2018 
75 
Confidential 
 
Grade 1  
Grade 2  
Grade 3  
Grade 4  
arrhythmia  
Hypophosphatemia 
2.0 - 2.4 mg/dL  
1.5 -1.9 mg/dL or 
replacement Rx 
required  
1.0 -1.4 mg/dL 
intensive therapy or 
hospitalization 
required  
< 1.0 mg/dL or 
abnormal 
phosphate with 
life-threatening 
arrhythmia  
Hyperbilirubinemi
a (when 
accompanied by 
any increase in 
other liver function 
test)  
1.1 - <1.25 x ULN  
1.25 - <1.5 x ULN  
1.5 – 1.75 x ULN  
> 1.75 x ULN  
Hyperbilirubinemi
a (when other liver 
function are in the 
normal range)  
1.1 - <1.5 x ULN  
1.5 - <2.0 x ULN  
2.0 – 3.0 x ULN  
> 3.0 x ULN  
BUN  
1.25 - 2.5 x ULN  
2.6 - 5 x ULN  
5.1 - 10 x ULN  
> 10 x ULN  
Hyperuricemia 
(uric acid)  
7.5 – 10.0 mg/dL  
10.1 – 12.0 mg/dL  
12.1 – 15.0 mg/dL  
>15.0 mg/dL  
Creatinine  
1.1 - 1.5 x ULN  
1.6 - 3.0 x ULN  
3.1 - 6 x ULN  
> 6 x ULN or 
dialysis required
ENZYMES  
AST (SGOT)  
1.1 - <2.0 x ULN  
2.0 – <3.0 x ULN  
3.0 – 8.0 x ULN  
> 8 x ULN  
ALT (SGPT)  
1.1 - <2.0 x ULN  
2.0 – <3.0 x ULN  
3.0 – 8.0 x ULN  
> 8 x ULN  
GGT  
1.1 - <2.0 x ULN  
2.0 – <3.0 x ULN  
3.0 – 8.0 x ULN  
> 8 x ULN  
Alkaline 
Phosphatase  
1.1 - <2.0 x ULN  
2.0 – <3.0 x ULN  
3.0 – 8.0 x ULN  
> 8 x ULN  
Lipase  
1.1 - 1.5 x ULN  
1.6 - 2.0 x ULN  
2.1 - 5.0 x ULN  
> 5.1 x ULN  
URINALYSIS  
Proteinuria  
1+ or 200 mg - 1 gm 
loss/day  
2-3+ or 1- 2 gm 
loss/day  
4+ or 2-3.5 gm 
loss/day  
nephrotic 
syndrome or > 
3.5 gm loss/day 
Hematuria  
microscopic only <10 
rbc/hpf  
gross, no clots >10 
rbc/hpf  
gross, with or without 
clots, OR red blood 
cell casts  
obstructive or 
required 
transfusion